medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



# THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19

Binh T. Ngo, M.D.1,2,*
Binh.ngo@med.usc.edu

Paul Marik, M.D., F.C.C.P., F.C.C.M.
Eastern Virginia Medical School|
Department of Internal Medicine|
Chief, Pulmonary and Critical Care Medicine|
825 Fairfax Ave, Rm 575, Norfolk, VA 23507|
marikpe@evms.edu

Pierre Kory, M.D., M.P.A
Pulmonary and Critical Care Medicine
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin .
pierrekory@icloud.com

Leland Shapiro, M.D.
Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and
University of Colorado Anschutz Medical Campus in Aurora, CO
Supported by The Emily Foundation in Boston, MA
lelandshapiro@cuanschutz.edu

Denise Brennan-Rieder P.h.D.
CoronaTracker Community Research Group
dbrennanrieder@gmail.com

Raphael Thomadsen, P.h.D.
Washington University in St. Louis
thomadsen@wustl.edu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Jose Iglesias, D.O., F.A.S.N.
Jersey Shore University Medical Center, Neptune NJ, Hackensack Meridian School of Medicine at Seton Hall
Jiglesias23@gmail.com

Stephen Ditmore, B.A.
Parkchester Times
stephen.ditmore@gmail.com

Marc Rendell, M.D.2,*
The Rose Salter Medical Research Foundation
Newport Coast, CA 92657
rendell@asndi.com

Joseph Varon, M.D., FACP, FCCP, FCCM, FRSM
United Memorial Medical Center
University of Texas School of Medicine
Houston, Texas, USA
joevaron@roamer.net

Michael Dubé, M.D.1
mdube@med.usc.edu

Neha Nanda, M.D.1
Neha.nanda@med.usc.edu

Gino In, M.D., M.P.H.1
Gino.In@med.usc.edu

Daniel Arkfeld,M.D. 1
arkfeld@med.usc.edu

Preet Chaudhary, M.D.1

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Preet.chaudhary@med.usc.edu

Vito M. Campese, M.D. 1
campese@med.usc.edu

Diana L. Hanna, M.D. 1
Diana.Hanna@med.usc.edu

David E. Sawcer, M.D. Ph.D.1
David.sawcer@med.usc.edu

Glenn Ehresmann, M.D.1
Glenn.ehresmann@med.usc.edu

David Peng, M.D., M.P.H.1
David.Peng@med.usc.edu

Miroslaw Smogorewski, M.D.1
smogorze@med.usc.edu

April Armstrong, M.D., M.P.H.1
April.armstrong@med.usc.edu

Rajkumar Dasgupta, M.D.1
"Dasgupta, Rajkumar" <rdasgupt@med.usc.edu>

Fred Sattler, M.D.1
fsattler@usc.edu

Cristina Mussini, M.D.
University of Modena and Reggio Emilia in Italy
Cristina.mussini@unimore.it

Oriol Mitja, Ph.D.
Hospital Universitari Germans Trias i Pujol
Badalona, Spain

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



omitja@flsida.org

Vicente Soriano, M.D. Ph.D.
UNIR Health Sciences School & Medical Center
C/ Almansa 101
Madrid 28040, Spain
Vicente.soriano@unir.net

Nicolas Peschanski, M.D., Ph.D
UniversityHospital of Rennes
Rennes, France
nicolas.peschanski@chu-rennes.fr

Gilles Hayem, M.D.
Hôpital Paris Saint-. Joseph, 75014
Paris, France.
ghayem@ghpsj.fr

Marco Confalonieri, M.D.
Azienda Ospedaliero-Universitaria di Trieste
Trieste, Italia
marco.confalonieri@asugi.sanita.fvg.it

Maria Carmela Piccirillo, M.D.
Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale
Napoli, Italia
m.piccirillo@istitutotumori.na.it

Antonio Lobo-Ferreira, M.D., Ph.D.
Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina da Universidade do Porto, Centro Hospitalar Universitário de São João, Porto, and Hospital Rainha Santa Isabel, Marco de Canaveses, Portugal
Aloboferreira@gmail.com

Iraldo Bello Rivero M.Sc., Ph.D.
Department of Clinical Investigations
Center for Genetic Engineering and Biotechnology,

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Ave 31 e/ 158 and 190. Cubanacan, Playa, 10600
Havana, Cuba.
iraldo.bello@cigb.edu.cu

Eivind H. Vinjevoll, M.D.
Volda Hospital HMR, Norway.
Eivind.vinjevoll@gmail.com

Daniel Griffin, M.D., Ph.D.[*,3]
ProHEALTH, an OPTUM Company
Columbia University
College of Physicians and Surgeons
Email: danielgriffinmd@gmail.com

Ivan FN Hung, MBChB, M.D., MRCP, FRCP.[*,3]
Li Ka Shing Faculty of Medicine
University of Hong Kong
Ivanhung@hku.hk

1 From the Keck Medical School of USC
2 From the Rose Salter Medical Research Foundation
3 CoSenior author
* Corresponding author

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



# ABSTRACT

**BACKGROUND.** The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World. As of November 1, 2020, there have been 45,942,902 confirmed cases of COVID-19, resulting in 1,192,644 deaths worldwide. Projections are for continued new infections and deaths if no effective therapeutic interventions can be initiated over the next several months. We performed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and by year end 2020.

**METHODS** Clinical Trials: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed as of September 15, 2020 on identified agents We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly observational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects, since smaller trial size could lack statistical power to establish superiority of the intervention over the control.

Publications: We searched for all published trial results on pubmed.gov and on medRxiv, the preprint server, and used a targeted Google™ search to find announcements of unpublished trial results

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



## RESULTS

Clinical Trials in Recruitment: We identified 663 trials currently in recruitment phase with subject size of 100 or more. Of these, 108 were directed at prevention in healthy individuals, 82 were classified as treatment of outpatients with documented infection, and 330 were for treatment of hospitalized inpatients.

Clinical trials Completed: As of November 15, 2020, there were only 80 studies with 100 or more subjects, including ; 49 trials in hospitalized patients, 9 directed at outpatients, and 10 prevention studies,

Published Data: As of November 1, 2020 we found 82 publications reporting findings in human studies on 12 classes of agents, and on 7 vaccines (See TABLE 2). There were 44 randomized or active controlled studies. The rest were retrospective observational analyses. Only 14 publications dealt with outpatient care, including 7 vaccine reports; the rest were all in hospitalized patients.

Available Treatments. At this time, remdesivir and convalescent plasma have been granted emergency use authorization in the U.S.A., solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. No treatments or prophylaxis are offered for outpatients.

CONCLUSION. COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few randomized, controlled outpatient studies expected to yield results in time to impact on the continuing pandemic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World's population.

Keywords: Coronavirus, COVID-19, SARS-Cov-2, remdesivir, hydroxychloroquine, favipiravir

## INTRODUCTION

SARS-Cov-2 spread with extraordinary speed from its origin in December 2019 in Wuhan, China. As of November 1, 2020, there have been 45,942,902 confirmed cases of COVID-19, resulting in 1,192,644 deaths worldwide affecting 220 countries and territories (1). This viral and multisystemic illness produces mild or no symptoms in about 80% of infected individuals, but, in about 20% manifests as pneumonia, which may progress to acute respiratory failure requiring assisted mechanical ventilation in up to 5% of patients (2). Symptomatic COVID-19 exhibits a characteristic sequence of events related to the primary viral attack, manifesting as an influenza-like illness with cough, fever, myalgias and fatigue. In patients destined for severe disease, within seven to 10 days of onset of symptoms, bilateral multiple lobar and subsegmental areas of consolidation are typically seen on chest computed tomography (CT) (See Figure 1) (3). Pneumonia can rapidly progress to acute respiratory failure with elevated cytokines suggesting an immune reaction as probable cause (4). Additionally, a coagulopathy develops which can affect the lungs and other organs, including triggering cerebrovascular thrombosis (5).

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



In mainland China, vigorous efforts to contain the spread of COVID-19 by home isolation, closure of business activity, travel bans, and tracking and control of contacts succeeded. As of November 1, China has had 91,921 confirmed cases with 4,746 deaths, but the number of new cases declined to low levels since April (1). Similar measures contained the epidemic in Korea, Taiwan and in New Zealand (1). In Hong Kong, one of the most densely populated areas in the world, universal masking, immediate hospitalization and early antiviral treatment for all confirmed cases have minimized the number of confirmed COVID-19 cases to 5,331 in a 7.5 million population with less than 3% requiring ICU care, and 105 fatalities (6). However, the disease was not similarly controlled in the rest of the World, particularly the United States (USA) where, despite only a fifth of the population of China, there have been 8,952,086 confirmed cases of COVID-19 with 228,185 deaths as of November 1, 2020 (1). In the USA, as in China, the response to the pandemic was through reduction of person-to-person contact. Beginning in early March, social gatherings and meetings ended; schools and businesses were closed along with recreation areas, parks, and beaches. These social distancing efforts blunted the spread of the disease, but not with the results achieved in China. Due to economic pressures, epidemiologic containment was relaxed resulting in a significant surge surpassing the original April peak.

Facing the growing crisis in early January, Chinese health authorities began treating patients empirically with agents with demonstrated *in vitro* antiviral activity against coronaviruses and those used during prior outbreaks of SARS 2003, H1N1 influenza of 2009 and MERS 2015(7). The medications included the antimalarial drugs hydroxychloroquine (HCQ) and chloroquine, the human immunodeficiency virus (HIV) protease inhibitor lopanovir-ritanovir (LPV/r), the Russian antiviral umifenovir, and

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



traditional Chinese medical approaches (8). Subsequently, HCQ was widely used to treat COVID-19 throughout the world, despite cautions from numerous regulatory bodies. The scientific basis for their use was *in vitro* evidence of an effect on blocking viral endosomal penetration, as well as a known suppressive benefit on undesirable autoimmune effects (9). Clinical studies thus far have been unsupportive.

Multiple vaccines are in clinical trials to assess safety and effectiveness, but these studies are unlikely to complete Phase III testing and proceed to mass vaccination until early 2021. In view of the continuing daily increase in new cases and deaths, our goal was to assess the options we have at the present time for release of pharmacologic agents to treat and to prevent COVID-19 while awaiting widespread immunization.

# METHODS

CLINICAL TRIALS: We reviewed up-to-date information from multiple sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop therapeutic interventions. We searched for investigational trials in active recruitment and those that have completed enrollment. We used (A) covid-

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



trials.org, a registry to collate all trials in real time with data pulled from the International Clinical Trials Registry Platform and all major national registries (10). We cross validated information on (B) clinicaltrials.gov, the registry of clinical trials information maintained by the United States National Library of Medicine. We further cross referenced the trials on (C) the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP).We excluded studies which were clearly observational for treatment purposes, with no randomization, control or comparison group. We further set a cutoff of 100 for numbers of subjects since smaller trial size typically lacks statistical power to enable regulatory approval. For each trial selected, we documented the setting of patient contact, either hospital or outpatient, the type of control procedure, the date the trial was initially registered, and the proposed date of completion of enrollment.

PUBLISHED TRIAL RESULTS: Our search was carried on the week of November 1, 2020. We identified all publications on pubmed.gov to find peer reviewed articles and on medRxiv to find preprint reports. We further carried out daily Google™ searches on each potential treatment to find preliminary reports, typically presented as press releases, reviewed by a journalist.

VIRTUAL DISCUSSIONS AMONG CO-AUTHORS: We used the preprint server medRxiv to post a systematic analysis of the development of therapeutic interventions for COVID-19 in order to stimulate diffusion of the manuscript and allow widespread “open source” input from co-authors (11). Successive versions have been posted periodically beginning in late May, 2020 and continuing to date.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



# RESULTS

REVIEW OF CURRENT TRIALS: As of November 1, 2020, we identified 663 trials currently in recruitment phase with subject size of 100 or more (Supplementary Table 1). Of these, 108 were directed at prevention in healthy individuals, 82 were classified as treatment of outpatients with documented infection, and 330 were for treatment of hospitalized inpatients. There were 9 trials focusing on the post discharge Tail phase. The remaining trials were unclear as to intended subjects. There were 44 vaccine trials, 120 trials of HCQ, 31 trials of alternative therapy, 11 trials of colchicine, 31 trials of anticoagulants, 13 trials of the RNA polymerase inhibitor favipiravir (FPV), 18 trials of glucocorticoid, and 53 trials of plasma based products. Closure of enrollment was projected by the end of the year for 105 trials.

COMPLETED TRIALS: As of November 1, 2020, there were 83 trials reporting completion with 100 or more subjects (Supplementary Table 2). Sixteen of these studies were of alternative medications. There were 49 trials in hospitalized patients, 8 directed at outpatients, and 11 prevention studies.

PUBLISHED RESULTS ON COVID-19 TRIALS: As of November 1, 2020 we found 82 publications reporting findings in human studies on 12 classes of agents, and on 7 vaccines (See TABLE 1). There were 44 randomized or active controlled studies. The rest were retrospective observational analyses. Only 14 publications dealt with outpatient care, including 7 vaccine reports; the rest were all in hospitalized patients.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



In the group of antiviral agents, the largest published randomized, controlled trials were with the intravenously administered RNA polymerase inhibitor remdesivir. The first multicenter trial conducted at ten hospitals in Hubei, China was halted in April due to lack of recruitment after 237 patients enrolled (12). Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87–1.75], decreased viral load, nor mortality benefit. A double blind, randomized placebo controlled trial of remdesivir, in 1062 moderate to severely ill patients was a carried out by the National Institute of Allergy and Infectious Disease (NIAID) (14). The patients who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI, 1.12 to 1.49; P<0.001). P<0.001). The Kaplan-Meier estimates of mortality by 29 days after randomization were 11.4% with remdesivir and 15.2% with placebo (hazard ratio, 0.73; 95% CI, 0.52 to 1.03). On the basis of this trial, the Food and Drug Administration (FDA) issued an emergency authorization for use of remdesivir for COVID-19 hospitalized patients. Subsequently, a report was published showing that in 397 hospitalized patients with moderate to severe disease, there was no difference in outcome comparing patients who received a 5 day course of remdesivir versus a 10 day course (15). There was no placebo arm. The 14 day mortality in the 5 day group was 8% versus 11% in the 10 day group. A different study of remdesivir in hospitalized patients with moderate COVID-19 clinical status showed improved clinical status by day 11 compared to standard of care for a 5 day course of remdesivir, but not for a 10 day course (16). Mortality at 28 days was 1% for patients in the 5 day group, 2% for those in the 10 day group, and 2% for the standard of care group. A retrospective analysis of a cohort of 312 patients with severe disease treated with remdesivir showed a mortality of 7.6%% compared to 12.5% in a different historical retrospective cohort of 818 patients treated with standard of care (17). There has been no data provided on viral clearance for the U.S. remdesivir studies. In early April,

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



the WHO organized a megatrial, appropriately named Solidarity, to assess four separate treatment options in hospitalized patients: (a) Remdesivir, an intravenously administered inhibitor of RNA polymerase; (b) LPV/R; (c) LPV/R plus Interferon β-1a; and (d) HCQ or Chloroquine (12). Results of the Solidarity Trial were reported by the World Health Organization on October 15, 2020. They found no effect of remdesivir on 28 day mortality, need for mechanical ventilation nor duration of hospitalization in a study including 5451 hospitalized patients (18).

There were two randomized, active control clinical trials in China of the orally administered RNA polymerase inhibitor favipiravir (FVP) (19, 20). In a study of 35 patients receiving FVP, compared to 45 patients receiving LPV/R plus inhaled interferon α, a shorter viral clearance time was found for the FVP arm (median (interquartile range, IQR), 4 (2.5–9) days versus 11 (8–13) days, $p < 0.001$) (19). The FVP arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.4% versus 62.2% ($p = 0.004$). In a larger Chinese trial comparing 116 patients on FVP to 120 on umifenovir, the 7 day clinical recovery rate was 55.9% for the umifenovir group and 71% in the FVP group (20). The Chinese Health Ministry, after reviewing the studies, concluded that FVP was efficacious against COVID-19. In Japan, a clinical registry containing 1918 hospitalized patients receiving FVP on a compassionate use basis was released on June 2, 2020 (21). There was no control group nor data on viral clearance. Patients were treated on average 3 days post admission to the hospital. The 30 day overall mortality was 11.6%. In Russia, a preliminary study of FVP showed reduced duration of viral shedding, and the drug was approved for clinical treatment beginning in multiple hospitals on June 12, 2020 (22). In India in July, Glenmark™ announced unpublished data on 150 patients confirming the favorable results of the Chinese studies, and FVP was released for treat-

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



ment in that country. In late September, a report, still unpublished, of a randomized controlled study in Japan announced more rapid viral clearance in FVP treated patients.

There were 21 published studies with HCQ. A group in Marseille reported their experience with 3737 patients screened positive for SARS-Cov-2 and immediately treated with HCQ and azithromycin (AZM), after excluding patients at risk of QT prolongation (23). Asymptomatic contacts with positive viral tests were included, so most of their subjects were outpatients seen in their day hospital in addition to those who did require hospitalization. They showed clearance of viral shedding in 89.4% of the patients by ten days. The overall mortality in their population was 0.9%, none in patients under 60 years old, and no sudden cardiac deaths. They had no randomized control population.

There have been many retrospective large observational trials which suggest that hospitalized patients on HCQ have worse outcomes with possible cardiac dysrythmias (See TABLE 1) (27-32). The difficulty in analyzing retrospective observational data is the possibility of selection bias choosing patients who were sicker for treatment.

In a randomized, controlled, Brazilian study, neither HCQ nor HCQ +AZM showed any clinical benefit in mild to moderate COVID-19 hospitalized patients (33). In the randomized RECOVERY trial in 1542 hospitalized patients in the United Kingdom, there was no significant difference in the primary endpoint of 28-day mortality (26.8% HCQ vs. 25% usual care; hazard ratio 1.09 [95% confidence interval 0.96-1.23]; $p$=0.18) (34). In the Solidarity Trial, there was no benefit of HCQ on mortality (HCQ

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), need for mechanical ventilation, nor duration of hospitalization(18).

In a retrospective comparison study at NYU Langone Health for all patients admitted between March 2 and April 5, 2020, there was a move to add zinc 100 mg daily to their standard HCQ plus AZM regimen (35). Zinc supplementation has shown benefit in viral diseases both in inhibiting viral replication, improvement of systemic immunity and reduction of duration of common cold symptoms There was a significantly lower mortality (13.1%) among the zinc treated patients compared to those who did not receive zinc (22.8%).

The prevailing current opinion on HCQ treatment of COVID-19 is based almost entirely on in-hospital data, with limited study in outpatients. In one internet-based prevention study, with HCQ given for 5 days to healthy individuals with a significant exposure to SARS-Cov-2, the incidence of new illness compatible with COVID-19 did not differ significantly between participants receiving HCQ (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); absolute difference −2.4 percentage points (95% confidence interval, −7.0 to 2.2; $p$=0.35) (36). The same group also treated 423 patients with mild symptoms imputed to COVID-19 (37). At 14 days, 24% (49 of 201) of participants receiving HCQ had ongoing symptoms compared with 30% (59 of 194) receiving placebo ($p$ = 0.21).

A study in Spain of 293 patients with PCR-confirmed mild COVID-19, found no difference in viral load nor risk of hospitalization following 6 days HCQ treatment compared to untreated patients (38).

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



The same group treated 1,116 healthy contacts of 672 Covid-19 index cases with HCQ while 1,198 were randomly allocated to usual care (39). There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ).

A large population study in Portugal surveyed all patients on chronic HCQ treatment and cross-verified against a mandatory database of patients registered with COVID-19 (40). The incidence of SARS-CoV-2 infection in patients receiving HCQ was 5.96%, compared to 7.45% in those not so treated. The adjusted odds ratio of a positive PCR test for HCQ chronic treatment was 0.51 (0.37-0.70). A randomized controlled study at the University of Pennsylvania found no evidence of benefit of two months prophylactic treatment with HCQ in 132 hospital workers SARS-Cov-2 infection rate HCQ 6.3% vs placebo 6.6%) (46).

Published results with Lopanovir/ritonavir (LPV/r) in hospitalized patients have been disappointing (47,48). In a randomized trial with 99 patients on LPV/r and 100 receiving standard care, there was no difference in time to clinical improvement, mortality or viral clearance (48). In the RECOVERY trial in 1,596 hospitalized patients there was no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18]; ($p$=0.58) (49). In the Solidarity Study, there was no effect of LPV/r on 28 day mortality LPV/r RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372), need for mechanical ventilation nor duration of hospitalization (18).

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



A possibly more favorable result was obtained in Hong Kong in a study of 86 patients assigned to triple combination therapy with LPV/r plus ribavirin plus interferon β-1 (50). Compared to a control group of 41 patients receiving LPV/r alone, the combination group had a significantly shorter median time from start of study treatment to negative SARS-Cov-2 nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4.37 [95% CI 1.86–10.24], *p*=0·0010). The time to complete alleviation of symptoms was 4 days [IQR 3–8] in the combination group vs 8 days [7–9] in the control group; HR 3.92 [95% CI 1.66–9.23. This study was interpreted not as supporting LPV/r therapy, but rather focusing on interferon β-1 as the primary treatment modality.

In Cuba, a combination of interferon-α-2b and interferon γ on background therapy of LPV/r and chloroquine was successful in achieving viral clearance in 4 days in 78.6% of the patients compared to 40.6% of those receiving interferon-α-2b alone (53). A study of 81 hospitalized patients in Iran showed 28-day overall mortality significantly lower in an interferon β treated group than the control group (19% vs. 43.6% respectively, *p*= 0.015) (54). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Interferon nasal drops were administered to 2944 medical staff people in Huabei province, with not a single case of COVID-19, but there was no randomized control group (55). Recently, a press release announced that a small British study of nebulized interferon β-1 had succeeded in reducing duration of hospitalization and mortality. In the Solidarity Study of hospitalized patients, there was no effect of interferon on 28 day mortality (IFN RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050), need for mechanical ventilation nor duration of hospitalization (18)

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



There have been many observational studies of immunomodulatory therapy with tocilizumab and anakinra to mitigate the pulmonary phase of COVID-19 which have suggested reduction of mortality and need for intubation in hospitalized severe and critically ill patients (31, 57-69). However, in several rtandomized control studies, there has been no benefit with tociliumab (70-72); in the randomized double blind COVACTA trial, there was no benefit of tocilizumab in clinical status, mortality (19.7% tocilizumab vs placebo = 19.4%), nor in ventilator free days (71). In the Cor-Immuno-Toci trial, there was no decrease in mortality at day 28, although there was a suggestion of improvement in the need for mechanical ventilation at day 14 (72). The tocilizumab results in the randomized controlled trials were affected by a higher frequency of glucocorticoid use in the control groups.

Pre-COVID-19, glucocorticoid treatment had been a recognized treatment with mortality benefit for patients in severe respiratory distress (73). In the RECOVERY trial, 2104 patients were randomly allocated to receive dexamethasone for ten days compared to 4321 patients concurrently allocated to usual care (74). Overall, 454 (21.6%) patients randomized to dexamethasone and 1065 (24.6%) patients receiving usual care died within 28 days (age adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; $p<0.001$). Dexamethasone reduced deaths by one-third in the subgroup of patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; $p<0.001$) and by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; $p=0.002$), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs.13.2%, RR 1.22 [95% CI 0.93 to 1.61]; $p=0.14$). Other glucocorticoids have shown similar benefits in COVID-19 patients with acute respiratory failure (75-81), al-

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



though a short 5 day course of methylprednisolone did not alter the very high mortality in a Brazilian study (79).

Colchicine, an anti-inflammatory agent, suggested benefit in the GRECCO, placebo-controlled, randomized clinical trial of 105 patients (82). The primary clinical end point of deterioration to mechanical ventilation or death was 14% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; p = 0.02).

There is also favorable data on convalescent plasma (83-87). A meta-analysis including 4173 patient outcomes across a multinational series of studies concluded that convalescent plasma treatment yielded a 57% reduction in mortality (86). Based on evidence of safety in over 20,000 patients in an expanded access program coordinated by the Mayo Clinic, the U.S. FDA recently issued an emergency authorization for use of convalescent plasma (87). However, convalescent plasma showed no benefit in a randomized controlled trial in India (88). Monoclonal antibodies to the SARS-COV-2 spike protein have been synthesized. Several recent press releases announced initial success in reducing viral loads with these antibodies.

A number of vaccines have reported successful induction of neutralizing antibody and cellular immune responses in early phase trials (91-97). Several vaccines are now in large scale studies preparing for submission for emergency use in the pandemic.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



# DISCUSSION

SARS-Cov-2 overwhelmed medical preparedness for the pandemic. Current projections are for a continuation of new cases and deaths through the end of 2020 (98, 99). Clinical trials to date have focused on hospitalized patients to try to prevent death. The modalities currently having emergency approval for treatment are solely directed at hospitalized patients. It is hoped that the use of remdesivir, convalescent plasma, glucocorticoids, anticoagulation and improved management of COVID-19 respiratory failure will lower the present rate of in hospital mortality which in some series has been as low as 6% but in most hospitals still approaches 20% (78). However, COVID-19 has several phases; the initial viral infection eventually leads to the inflammatory/pulmonary phase which requires hospital treatment. It is essential to change the present dynamic of attempted therapeutic responses to distinguish specific phases (100). In particular, efforts must now focus on prevention and treatment of the initial viral infection so that hospitalization can be avoided. We face a dilemma in having no current prevention nor treatment for outpatients with mild to moderate disease, constituting 80% of the infected population and the primary mode of spread of SARS-Cov-2. The lessons learned in very sick hospitalized patients do not necessarily apply to the earlier viremic phase. Antiviral agents, such as remdesivir and favipiravir, convalescent plasma, and monoclonal antibodies are likely to be most effective during the early stage of viremia, which is prehospitalization.

Vaccines have been the sole hope held out by public health authorities to arrest SARS-Cov-2 in the early viremic phase. Progress on vaccine development has been rapid, but the speed of development

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



does not reduce the challenges of developing a vaccine to be administered to hundreds of millions of people. Certainly the 30 years of as yet unsuccessful efforts to produce an AIDS vaccine illustrate the worst case difficulties. Although neutralizing antibodies and memory T cells can be produced by the vaccine candidate, the demonstration of true protection requires observation and long-term follow-up of an exposed vaccinated population. No matter how rapidly a vaccine advances to Phase III testing, the duration of follow-up cannot be shortened, and for SARS-Cov-2 possibly prolonged due to several factors. First, there is a risk of immune enhancement of infection which occurs when induced antibodies increase entry and internalization of virus into myeloid cells (101). This major complication struck the newly developed dengue vaccine in 2017 (102). Second, the sinister autoimmune pathogenicity of SARS-Cov-2 raises the risk of delayed long-term harm if the virus is not fully and immediately eradicated by the initial immune response to the vaccine. Finally, the duration of protection is an open question. Studies of recurrent coronavirus infections suggest that infection may confer immunity for less than a year (103). For these reasons of needed long term safety observation, the deployment of an effective vaccine could be delayed. Furthermore, efforts to find volunteers for vaccine trials will be hampered if there is no treatment available for placebo treated patients who become infected.

Shortages of testing supplies in the United States have thus far limited the ability to positively diagnose the disease, resulting in the recommendation of home quarantine for the majority of patients with suspicious symptoms. Those shortages are being remedied. Now, there is a need for therapeutic interventions which can be used to treat outpatients with positive COVID-19 tests at the time of initial symptoms, not waiting for deterioration requiring hospital care. The Marseille group treated all outpatients with a positive COVID-19 test early in the viremic phase (23). They provided clinical and

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



virologic data, but without a well-defined control group to justify their treatment with HCQ plus AZM. The NYU group treated all hospitalized patients with HCQ and AZM, and showed an impressive effect of addition of zinc sulfate, but they had no control group for HCQ plus AZM (35). Remdesivir administered intravenously for five days is not a practical daily outpatient treatment; Gilead© is attempting to develop an inhaled remdesivir formulation, but those efforts are only now beginning. Favipiravir, a tablet, could be used in early stages of infection and has now been released in Russia and in India, but not in the United States. It has known embryogenic risks, so its use requires restrictions on women of childbearing potential, as is the case with tretinoin for acne and thalidomide for multiple myeloma. Trials with camostat, the serine protease inhibitor, capable of blocking cell entry of SARS-Cov-2, are not due to end till the third or fourth quarter of the year. Similarly, a prevention trial with colchicine is not scheduled to end until the fourth quarter of 2020. Convalescent plasma has been approved for emergency use in hospitalized patients. An infusion could be delivered to outpatients. Monoclonal antiviral neutralizing antibodies based on the same principle are under study to prevent nursing home outbreaks, and have shown initial success in ambulatory patients. But, at this time, no outpatient therapy has been proven safe and effective in a phase III randomized, placebo-controlled study. There are strong arguments to avoid emergency use of agents until trials are completed and analyzed, but the agents suggested are not new. Most are drugs like the interferons, marketed and available for other conditions and with well-known safety profiles. There is a clear need for outpatient therapeutic intervention now.

There is a precedent to resolve the conflict between immediate clinical need and the requirements for rigorous controlled trials to prove efficacy. We should remember that the greatest success in fighting a

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



pandemic occurred over the past two decades in the battle against the HIV virus which causes AIDS. AIDS was first recognized in 1981 in the MSM (men who have sex with men) community (104). The disease was considered a death sentence. There was widespread fear because there was no treatment, and projections of infection escalated into the millions. The first AIDS remedy was azidothymidine (AZT), synthesized in 1964 in the hope that it would combat cancer. Twenty years later Dr. Samuel Broder, head of the National Cancer Institute, showed that the drug had activity against the HIV virus in vitro (105). Burroughs Wellcome launched a rapidly conceived trial with just 300 patients. They stopped the trial in 16 weeks claiming that more patients survived on AZT. The FDA came under enormous pressure from AIDS activists to make the drug available, and it was approved on March 19, 1987, with only that one trial. It had taken 20 months for the FDA to give approval to release the drug. To this day, the design and results of the trial remain controversial.

The LGBT community continued to battle for early release of other medications to combat the AIDS pandemic. On October 11, 1988, a massive protest occurred at the FDA. It was back then Dr. Anthony Fauci who publicly advanced the idea of a parallel track to make drugs widely available even while studies are progressing: "*Clearly, the standard approach to the design of clinical trials—that is, rigid eligibility criteria as well as the strict regulatory aspects that attend clinical trial investigations and drug approval—was not well-suited to a novel, largely fatal disease such as this with no effective treatments, and we had many intense discussions about how to make that approach more flexible and ethically sound. One example, which I and others worked closely with the AIDS activists to develop, was called a parallel track for clinical trials. The parallel track concept, which the United States Food and Drug Administration ultimately came to support, meant that there would be the standard type of highly*

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



*controlled admission criteria and data collection for the clinical trial of a particular drug. In parallel, however, the drug also could be made available to those who did not meet the trial's strict admission criteria but were still in dire need of any potentially effective intervention, however unproven, for this deadly disease*" (106).

The parallel track advocated by Dr. Fauci was adopted. Today, there are 41 drugs or combinations approved by the FDA to treat and to prevent HIV infection. There is still no vaccine. There are now an estimated 1.1 million patients with HIV in the United States, most enjoying near normal life expectancy thanks to the antiviral agents. The CDC has contributed greatly to limit the spread of HIV by advocating safe sex practices, but social distancing is not the norm for HIV. Rather "treatment as prevention" for people with HIV using highly active antiretroviral regimens to prevent transmission as well as pre-exposure prophylaxis with a daily antiviral combination pill are currently endorsed by the CDC and adopted in wide segments of the at risk population 107).

In this pandemic crisis, we appeal to public health authorities to change the dynamic of current studies to outpatient care and to cross institutional, commercial and international boundaries to collate and combine all randomized controlled data submitted for all agents in Europe, China, Russia, Japan, India and other countries, and by competing companies, whether officially published, posted on line, or unpublished to finalize confirmatory results. The Solidarity Trial is a model of what could and should be done to unify a worldwide effort to pursue randomized controlled studies in outpatients. At the same time, agents with favorable preliminary results and no safety issues should be made available through a parallel track. In Russia and India, the parallel track has been fully implemented, with FVP now offered

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



as treatment throughout both countries, even as further confirmatory controlled trials proceed. The interferons are widely available in most countries. If vaccines can be brought forward now, it is reasonable to authorize their use at present in very large parallel track studies in at risk populations, such as healthcare workers and the elderly. China has begun vaccinating their military with one of their vaccines. Russia is proceeding to a voluntary vaccination program. The United Kingdom and the U.S. Centers for Disease Control are considering an emergency authorization program for vaccines before conclusion of the ongoing Phase 3 trials. However, it is unwise to rely solely on the hope for eventual mass vaccination to stop SARS-Cov2. Antiviral medication has succeeded in limiting HIV, and antivirals are just as important as annual vaccination for control of influenza. It is necessary for public health authorities to make hard decisions now despite limited current data and offer outpatient treatments on a broad front with no further delay.

## REFERENCES

1) WHO Coronavirus Disease (COVID-19) Dashboard

Data last updated: 2020/11/01 143 PM

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



2) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-1242

3) Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.

4) Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Apr 17 https://doi.org/10.1111/jth.14849.

5) Ricardo J, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation storm: Lancet Respir Med 2020; 8(6): e46-e47

6) https://www.nature.com/articles/d41586-020-01248-1

7) Park M, Ryan S, Thwaites RS, et al. COVID-19: Lessons from SARS and MERS Eur J Immun 2020; 50(3): 308-311

8) China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition 2020-03-16 12:00:32

9) Liu J, Cao R, Xu M,et al. Cell Discovery. 2020; 6:16 Cell Discovery https://doi.org/10.1038/s41421-020-0156-0www.nature.com/celldisc

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



10) Thorlund KT, Dron L, Park J et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health 2020; 2: e86-e87 published on line 24 Apr 20 https://doi.org/10.1016/ S2589-7500(20)30086-8

11) Ngo BT, Rendell M. A systematic analysis of the time course to develop treatments for COVID-19medRxiv 2020.05.27.20115238; doi: https://doi.org/10.1101/2020.05.27.20115238

12) Wang Y, Zhang D, Guanhua Du G, et al. Remdesivir in adults with severe COVID-19: a randomised,double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569-1578

13) Grein J, Ohmagari N, Shin D et al. Compassionate use of remdesivir for patients with severe Covid-19N Engl J Med 2020; 328: 2327-2336

14) Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 — final Report. October 8, 2020 DOI: 10.1056/NEJMoa2007764

15) Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med May 27, 2020 DOI: 10.1056/NEJMoa2015301

16) Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial .JAMA. Published online August 21, 2020. doi:10.1001/jama.2020.16349

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



17) Olender SA, Perez KK, Go AS, et al . Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clinical Infectious Diseases, ciaa1041, https://doi.org/10.1093/cid/ ciaa1041 Published: 24 July 2020

18) WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020. .https://doi.org/10.1101/2020.10.15.20209817 posted Oct 15, 2020

19) Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study Engineering (Beijing). 2020;10.1016/j.eng.2020.03.007. doi:10.1016/j.eng.2020.03.007

20) Chen C, Huang J, Zhenshun Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037432.this version posted March 20, 2020.

21) Preliminary Report of the Favipiravir Observational Study in Japan Favipiravir Observational Study Group. http://www.kansensho.or.jp/uploads/files/topics/ 2019ncov/ covid19_casereport_ en_200529.pdf Accessed 19 June 2020

22) Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a Phase II/III multicenter randomized clinical trial. Clinical Infectious Diseases, ciaa1176, https://doi.org/10.1093/cid/ciaa1176

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



23) Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 July-August; 36: 101791. . Available on line 25 June 2020

24) Chen Z, Hu J,Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv preprint doi:https://doi.org/10.1101/2020.03.22.20040758.this version posted March 30, 2020.

25) Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ (Med Sci) 2020, Vol. 49 Issue (1): 0-0 DOI: 10.3785/j.issn.1008-9292.2020.03.03

26) Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. BMJ 2020;369:m1849

27) Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med (2020), https://doi.org/10.1016/ j.medj.2020.06.001

28) Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med 2020 ;382(25):2411-2418

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



29) Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323(24): 2493-2502.

30) Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844

31) Ip A, Berry DA, Hansen E, et al, Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - An observational study. PLoS ONE 15(8): e0237693.

32) Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Inf Dis. 2020 ; 97: 396–403

33) Cavalcanti AB. Zampieri FG, Rosa RG, et al .Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New Eng J Med published on line July 23, 2020 DOI: 10.1056/NEJ-Moa2019014

34) RECOVERY Collaborative Group. Effect of Hydroxychloroquine in hospitalized patients

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



with COVID-19. New Engl J Med October 8, 2020

DOI: 10.1056/NEJMoa2022926

40) Carlucci P, Tania Ahuja T, Petrilli CM, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients medRxiv doi: https://doi.org/10.1101/2020.05.02.20080036

41) Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med J 2020; 383:517-525

42) Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19.A randomized trial. Ann Int Med2020 Jul 16 : M20-4207

43) Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clinical Infectious Diseases, ciaa1009, https://doi.org/10.1093/cid/ciaa1009 Published: 16 July 2020

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



44) Mitjà O, Ubals M, Corbacho-Monné M, et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. medRxiv 2020.07.20.20157651; doi: https://doi.org/10.1101/2020.07.20.20157651

45) Ferreira A, Oliveira-e-Silva A ,Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol 2020:1-5J Med Virol. 2020;1–5 DOI: 10.1002/jmv.26286

46) Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers. A randomized clinical trial JAMAInternMed.doi:10.1001/jamainternmed.2020.6319 PublishedonlineSeptember30,2020.

47) ) Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI.Med (N Y). 2020 May 19 doi: 10.1016/j.medj.2020.04.001

48) Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.

49) RECOVERY Collaborative Group. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Published On-line October 5. 2020 https://doi.org/10.1016/ S0140-6736(20)32013-4.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



50) Hung IFN , Lung KC, Tso EYK et al Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Lancet,2020 May 30;395(10238):1695-1704.

51) Estebanez M, Ramirez-Olivencia G, Mata T, et al. Clinical evaluation of IFN beta-1-b in COVID-19 pneumonia: a retrospective study. MedRxiv doi: https://doi.org /10.1101/ 2020.05.15.20084293

52) Pereda R, González D, Rivero HB, et al. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience. medRxiv preprint doi: https:// doi.org/10.1101/ 2020.05.29.20109199.

53) PE Idelsis, Perez-Escribano J, Duncan-Robert Y, et al Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA medRxiv https://doi.org/10.1101/2020.07.29.20164251

54) Rahmani H, Davoudi-Monfared E,, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020 Nov; 88: 106903. Published online 2020 Aug 24. doi: 10.1016/j.intimp.2020.106903

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



55) Meng Z, Wang T, Chen L, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. medRxiv .https://doi.org/10.1101/ 2020.04.11.20061473

56) Bian H, Zheng ZH, Wei D. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv doi:https://doi.org/10.1101/ 2020.03.21.20040691

57) Xua X, Hanb M, Lia T, et al. Effective treatment of severe COVID-19 patients with tocilizumab 10970–10975 | Proc Natl Acad Sci | May 19, 2020 | vol. 117 | no. 20 www.pnas.org/cgi/doi/10.1073/ pnas.2005615117

58) Somers EC, Eschenauer GA, Troost JP. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. MedRxiv doi: https://doi.org/10.1101/2020.05.29.20117358

59) Rossi B, Nguyen LS, Zimmermann, et al. Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study medRxiv doi: https://doi.org/ 10.1101/2020.06.06.20122341

60) Martinez-Sanz J, Muriel A, l Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A Multicenter Cohort Study. MedRxiv doi: https://doi.org/ 10.1101/2020.06.08.20125245

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



61) Petrak R, Skorodin N, Van Hise N, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. MedRxiv doi: https://doi.org/10.1101/ 2020.06.05.20122622

62) Perrone P, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. MedRXiv doi: https://doi.org/10.1101/2020.06.01.20119149

63) Garcia EM, Caballero VR, Albiach L,et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection medRxiv doi: https://doi.org/ 10.1101/2020.06.05.20113738

64) Wadud N, Ahmed N, Shergil M, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. MedRxiv doi: https:// doi.org/10.1101/2020.05.13.20100081

65) Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.doi: https://doi.org/10.1101/2020.05.07.20094599

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



66) Ramaswamy M, Mannam P, Comer R, et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: A case-control study medRxiv. doi: https://doi.org/10.1101/2020.05.14.20099234

67) Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2(8): 2, e474-e484

67) Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2: e325–31

68) Cauchois R, Koubia M, Delarbreb D, et al. Early IL-1 receptor blockade in severe inflammato-ryrespiratory failure complicating COVID-19. Proc Nat Acad Sci 2020; 117: 18951-18953

69) Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020; 2: e393-e400

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



70) Salvarani, C; Giovanni Dolci D, MD3; Marco Massari M et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia

JAMA Intern Med. Published online October 20, 2020. doi:10.1001/jamainternmed.2020.6615

71) Rosas IO, Bräu N,, Waters M, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia posted September 12, 2020. medRxiv.https://doi.org/10.1101/2020.08.27.20183442doi:

72) Hermine O, Mariette X, Tharaux PL, et al .Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. A randomized clinical trial

Published Online: October 20, 2020. doi:10.1001/jamainternmed.2020.6820

73) Villar J, Ferrando C, Martínez D et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276

74) RECOVERY Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. July 17, 2020 DOI: 10.1056/NEJMoa2021436

75) Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv preprint doi: https://doi.org/ 10.1101/2020.06.17.20134031.this version posted June 25, 2020

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



76) Fadel R ,Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-1. Clinical Infectious Diseases 2020; ciaa601, https://doi.org/10.1093/cid/ciaa601

77) Villar J, Confalonieri, M, Pastore, SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by Coronavirus Disease 2019. Crit Care Explor April 2020;2 :e0111

78) Marik PE, Kory P, Varon J, et al. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale, Expert Review of Anti-infective Therapy https://doi.org/ 10.1080/14787210.2020.1808462 published on line 18 aug 2020

79) Jeronimo CMP, Farias MEL, BSc, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase iib, placebo-controlled trial Clinical Infectious Diseases, ciaa1177, https://doi.org/10.1093/cid/ciaa1177

80) Dequin PF, Nicholas Heming NMD, PhD4,5; Mezian F, et a; Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19, A randomized clinical trial JAMA. 2020;324(13):1298-1306. doi:10.1001/jama.2020.16761

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



81) Chroboczek T, Lacoste L, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. MedRxiv: doi: https://doi.org/ 10.1101/2020.05.08.20094755

82) Deftereos SG, Giannopoulos G, Dimitrios A, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus Disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open. 2020;3:e2013136.

83) Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020 ;324(5):460-470.

84) Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Haematologica. 2020 Jul 23;haematol.2020.261784. doi: 10.3324/haematol.2020.261784

85) Avendano-Sola C, Ramos-Martinez A,Munez-Rubio E, et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. MedRxiv September 1, 2020. .https://doi.org/ 10.1101/2020.08.26.20182444doi:

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



86) Joyner MJ, Klassen SA, Senefeld JW, et al. ,Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. MedRxiv posted August 28, 2020.https://doi.org/ 10.1101/2020.07.29.20162917doi: medRxiv pr

87) Joyner MJ, Bruno KA, Klassen SA, et al, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Mayo Clin Proc. 2020;95 (9):1888-1897

88) Agarwal A, Mukherjee A, Kumar g, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) s: BMJ 2020;371:m3939 http://dx.doi.org/10.1136/bmj.m3939

89) Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology. 2020 May 22 doi: 10.1053/j.gastro.2020.05.053 [Epub ahead of print]

90) Rajter JC, Sherman M, Fatteh N, et al. ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv doi: https://doi.org/10.1101/2020.06.06.20124461

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



91) Folegatti PM, J Ewer KJ, Parvinder K Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 ;396(10249):467-478

92) Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 —preliminary report N Engl J Med. 2020 Jul 14;NEJMoa2022483.

doi: 10.1056/NEJMoa2022483

93) Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo controlled, phase 2 trial. Lancet 2020; 395(10240):, P1845-1854, June 13, 2020

94) Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine..New Engl J Med. DOI: 10.1056/NEJMoa2026920

95) Xia S, Duan K, Yuntao Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. Interim analysis of 2 randomized clinical trials. JAMA 2020 ;e2015543.doi: 10.1001/jama.2020.15543

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



96) Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. Published online September 4, 2020 https://doi.org/10.1016/S0140-6736(20)31866-31

97) Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. [published online ahead of print August 12, 2020] Nature 2020

98) Liu M, Thomadsen R, Yao S. Forecasting the spread of COVID-19 under different reopening strategies. medRxiv preprint doi: https://doi.org/10.1101/2020.05.26.20113993

99) Institute for Health Metrics and Evaluation. COVID-9 projections . Covid 19.healthdata.org

100) Marik PE, Varon J, Kory P. Treatment of Covid-19 is critically phase specific. Crit Care Shock 2020;23 :10-12

101) Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94:e02015-19.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



102) Fatima K, Syed NI. Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health. 2018; 8(2): 020312.

103) Edridge AWD, Kaczorowska J, Hoste ACR et al. Coronavirus protective immunity is short-lasting.medRxiv preprint doi: https://doi.org/10.1101/2020.05.11.20086439.this version posted June 16, 2020.

104) Sepkowitz KA. AIDS-The first 20 years. N Engl J Med 2001; 344 (23):1764-1772

105) Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85(1): 1-18

106) Fauci AS. Preface: Evolving ethical issues over the course of the AIDS pandemic. Public Health Rev 34, 2 (2012)

107) Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of human immunodeficiency virus testing, viral suppression, and HIV pre-exposure prophylaxis - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019; 68 (11):1117-1123

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint
**(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

TABLE 1. PUBLISHED STUDIES AS OF NOVEMBER 1, 2020. Each agent is listed along with the country originating the publication. The type of control procedure: RCT: Randomized controlled study PLAC: Placebo , soc: standard of care which is variable depending on each location. AC: Active control: the control options are listed in parenthesis. OBS: retrospective observation study. LPV/R: lopanovir/ritonavir; HCQ: hydroxychloroquine; AZM: azithromycin; IFN: interferon; tocilizumab: TCZ. SEV: severe; CRIT: critical; MOD: moderate. W.H.O.: World Health Organization

| TREATMENT | LOCATION | TYPE OF CONTROL | NUMBER SUBJECTS | SETTING | SEVERITY | RESULTS |
|---|---|---|---|---|---|---|
| Remdesivir[12] | China | RCTPLAC vs soc | 273 | HOSP | SEV | mortality in remdesivir group 14%, control 13%<br>11% in remdesivir group with <10 days symptoms<br>Vs 14% in placebo group, no difference in viral clearance |
| Remdesivir[13] | U.S.A. | OBS. | 53 | HOSP | SEV,CRIT | Mortality 18% (6 of 34 patients on mechanical ventilation<br>5% 1 of 19 of those not receiving mechanical ventilation |
| Remdesivir[14] | U.S.A. | RCTPLAC | 1062 | HOSP | SEV,CRIT | 29 day mortality 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03) |
| Remdesivir[15] | U.S.A. | AC(5 day vs 10 day, no control) | 397 | HOSP | MOD,SEV | 10 day group had more severe disease, mortality 8% in 5 day group 11% in 10 day group |
| Remdesivir[16] | U.S.A. | AC(5 day vs 10 day, vs soc) | 596 | HOSP | MOD | Improved clinical status in 5 day group but not in10 day group |
| Remdesivir[18] | W.H.O. | AC( 10 day, vs soc) | 5451 | HOSP | MOD,SEV | Mortality Remdesivir RR=0.95 (0.81-1.11, p=0.50 301/2743 active vs 303/2708 control |

| | | | | | | |
|---|---|---|---|---|---|---|
| (Favipiravir) FVP[19] | China | AC(lpv/r vs favipiravir) | 70 | HOSP | MOD,SEV | 4 day viral clearance time FPV vs 11 days lpv/r<br>CT scan improvement 92% fvp vs 62% lpv/r |
| FVP[20] | China | AC (umifenovir vs favipiravir) | 240 | HOSP | MOD,SEV | Clinical recovery rate 56%umifenovir vs 71% fvp<br>time to fever reduction and cough shorter fvp |
| FVP[21] | Japan | OBS (no control) | 1918 | HOSP | MOD,SEV,CRIT | Mortality 11.6% at one month |
| FVP[22] | Russia | AC (vs soc) | 60 | HOSP | MOD | viral clearance achieved in 25/40 (62.5%) patients on fvp vs 6/20 (30.0%) patients on SOC (p=0.018) |
| HCQ[23] | France | OBS(hcq+azm, noncomparable control group) | 3737 | MIXED | MILD,MOD | 0.9% overall mortality, no sudden death, no cardiac arrythmias |
| HCQ[24] | China | RCT(soc) | 62 | HOSP | MOD | shorter time to temperature recovery<br>Pneumonia improvement 81% (HCQ) vs 55% soc<br>no progression to severe status any HCQ patient versus 4 of 17 (soc) |
| HCQ[25] | China | RCT(soc) | 30 | HOSP | MOD | no differences in viral clearance time |
| HCQ[26] | China | RCT(hcq vs soc) | 150 | HOSP | MILD,MOD | No difference in viral clearance at 28 days |
| HCQ[27] | U.S.A. | OBS(hcq vs no hcq) | 338 | HOSP | MOD,SEV | Mortality twice as high in patients chosen for HCQ treatment |

| | | | | | | |
|---|---|---|---|---|---|---|
| HCQ[28] | U.S.A. | OBS (hcq vs no hcq) | 1376 | HOSP | MOD,SEV | no significant association between HCQ use and intubation or death<br>(hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32).<br>HCQ treated patients were sicker with ppO2 223 vs 360 for controls<br>still lower than controls after propensity score matching 223 vs 273 |
| HCQ[29] | U.S.A. | OBS (hcq+azt vs hcq vs azt) | 1438 | HOSP | MOD,SEV | Overall in-hospital mortality was 20.3%,25.7% hcq+azt, 19.9% hcq alone<br>neither drug 17.7%, cardiac arrest more likely with hcq+azt |
| HCQ[30] | France | OBS (hcq vs no hcq) | 181 | HOSP | MOD,SEV | no difference in mortality or need to transfer to ICU |
| HCQ[31] | U.S.A. | OBS (hcq vs hcq plus azm, azm | 1914 | HOSP | MOD,SEV | 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, |
| HCQ[32] | U.S.A. | OBS (hcq vs hcq plus azm, azm | 2541 | HOSP | MOD,SEV | Overall mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hcq+azt, (20.1% [95% CI: 17.3%-23.0%]), hcq alone, (13.5% [95% CI: 11.6%-15.5%]), azt alone,(22.4% [95% CI: 16.0%-30.1%]), neither drug, (26.4% [95% CI: 22.2%-31.0%]). |
| HCQ[38] | Brazil | RCT (hcq+azm, hcq, vs soc) | 504 | HOSP | MILD,MOD | No difference in clinical status of patients or mortality at 15 days |
| HCQ[39] | U.K. | RCT (hcq vs soc) | 1542 | HOSP | MOD,SEV | no significant difference in28-day mortality (26.8% hydroxychloroquine vs. 25% usual care; |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | hazard ratio 1.09 [95% confidence interval 0.96-1.23]; p=0.18) ( |
| HCQ[23] | W.H.O. | AC( vs soc) | 1853 | HOSP | MOD,SEV | Mortality RR=1.19 (0.89-1.59, p=0.23; 104/947 HCQ vs 84/906 control |
| HCQ[40] | U.S.A. | OBS (hcq+azt +zinc vs hzq +azt) | 932 | HOSP | MOD,SEV | Reduction in mortality with addition of zinc OR 0.449, 95% CI 0.271-0.744). |
| HCQ[41] | U.S.A. | RCTPLAC | 821 | OUTPAT | HEALTHY | No significant difference in incidence of subsequent COVID-19 infection (11.8% HCQ, 14.3% PLAC, p=0.35) |
| HCQ[42] | U.S.A. | RCTPLAC | 423 | OUTPAT | MILD | At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21) |
| HCQ[23] | W.H.O. | AC( 10 day, vs soc) | 5042 | HOSP | MOD,SEV | Mortality HCQ RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906 |
| HCQ[43] | Spain | RCTPLAC | 293 | OUTPAT | MILD | no difference in viral load at 7 days after 6 days HCQ treatment nor risk of hospitalization compared to untreated patients |

| | | | | | | |
|---|---|---|---|---|---|---|
| HCQ[44] | Spain | RCTPLAC | 2324 | OUTPAT | HEALTHY | no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ) |
| HCQ[45] | Portugal | OBS(HCQ vs no HCQ) | 1293 | OUTPAT | HEALTHY | odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ 0.51 (0.37-0.70). |
| HCQ[46] | U.S.A. | RCTPLAC | 132 | OUTPAT | HEALTHY | 2 month treatment with HCQ in hospital workers no significant difference in SARS-Cov-2 infection rate HCQ 6.3% vs placebo 6.6% |
| LPV/r[47] | China | AC(lpv/r vs umifenovir vs no antiviral) | 44 | HOSP | MOD,SEV | No differences in viral load, clinical status, or CT scan |
| LPV/r[48] | China | RCT(soc) | 199 | HOSP | SEV | No differences in mortality, viral load; time to clinical improvement 1 day less in lpv/r group |
| LPV/r[49] | U.K. | RCT(soc) | 1596 | HOSP | MOD,SEV | no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18];( p=0.58) |
| LPV/r[23] | W.H.O. | AC( LPV/r vs soc) | 2771 | HOSP | MOD,SEV | Mortality LPV/r (RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372 |

| | | | | | | |
|---|---|---|---|---|---|---|
| LPV/r[50] | Hong Kong | AC(lpv/r+ribavirin+beta interferon vs lpv/r+ribavirin) | 2772 | HOSP | MOD.SEV | Triple combination of interferon beta-1b, lpv/r, and ribavirin yielded more rapid viral clearance but attributable primarily to interferon |
| IFN- β-1a[51] | Cuba | OBS | 761 | HOSP | MIXED | Case fatality ratio 0.92 for interferon treated patients |
| IFN-α-2b[52] | Cuba | AC(RCT ( IFN- α-2b- vs IFN-α-2b + IFN- γ, background LPV/R +chloroquine) | 66 | HOSP | MIXED | Time to reach the elimination of Viral clearance 3 days for combined interferons vs 5 days for IFN- α-2b alone (p=0.0027 |
| IFN- β-1a[63] | Iran | RCT ( IFN- β-1a vs soc) | 81 | HOSP | SEV,CRIT | 28-day overall mortality significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118) |
| IFN[23] | W.H.O. | AC( vs soc) | 4100 | HOSP | MOD,SEV | Mortality IFNRR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050) |
| IFN-α nasal drops[54] | China | OBS | 2944 | OUTPAT | HEALTHY | No cases of COVID-19 compared to historical control |
| Meplazumab[55] | China | RCT(soc) | 38 | HOSP | MOD,SEV | Viral clearance 3 days (1.5-4.5) compared to 13 days(6.5-19.5) in control group |
| Tocilizumab(TCZ)[56] | China | OBS(no control) | 20 | HOSP | SEV,CRIT | no patient died, rapid defervescence, improvement in oxygenation |

| | | | | | | |
|---|---|---|---|---|---|---|
| TCZ[36] | U.S.A. | OBS (TCZ vs soc) | 1914 | HOSP | CRIT | 30 day unadjusted mortality with and without TCZ of 46% versus 56% |
| TCZ[57] | U.S.A. | OBS (TCZ vs soc) | 154 | HOSP | CRIT | TCZ was associated with a 45% reduction in hazard of death [hazard ratio 0.55 (95% CI 0.33, 0.90)] |
| TCZ[58] | France | Matched cohort (TCZ vs soc) | 168 | HOSP | SEV | TCZ was associated with a 51% reduction in composite of death and mechanical ventilation(HR)=0.49 (95% confidence interval (95CI)=0.3-0.81), p-value=0.005) |
| TCZ[59] | Spain | OBS | 1229 | HOSP | SEV | TCZ associated with decreased risk of death (aHR 0.34, 95% CI 0.16 to 0.72, p=0.005) and ICU admission or death (aHR 0.38, 95% CI 0.19 to 0.81, p=0.011) among patients with baseline CRP >150 mg/L, |
| TCZ[60] | U.S.A. | OBS (TCZ early vs late treatment)) | 154 | HOSP | CRIT | increased survival and avoidance mechanical ventilation with early treatment |
| TCZ[61] | Italy | OBS | 1221 | HOSP | SEV | 15.6% moratility at 14 days, 20% at 30 days in TCZ treated patients |
| TCZ[62] | Spain | OBS( TCZ vs soc) | 171 | HOSP | MOD,SEV | TCZ associated with decreased risk OF ICU admission (10.3% vs. 27.6%, P= 0.005) and |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | need of invasive ventilation (0 vs 13.8%, P=0.001) |
| TCZ[63] | U.S.A. | OBS (TCZ vs soc) | 94 | HOSP | CRIT | Survival rate 48 % in the control group and 61% in patients who received TCZ P < 0.00001. |
| TCZ[64] | Spain | OBS( TCZ vs soc) | 82 | HOSP | CRIT | 7 day mortality with TCZ 26.8%. Age adjusted HR 2.1 if TCZ begun after onset of respiratory failure |
| TCZ[65] | U.S.A. | OBS (TCZ vs soc) | 86 | HOSP | SEV | Reduced risk of death in patients who received TCZ (RR 0.472; 95% CI 0.449-0.497 P < 0.00001) |
| TCZ[66] | Italy | OBS(TCZ vs soc) | 544 | HOSP | SEV | TCZ treatment was associated with a reduced risk of invasive mechanical ventilation or death (adjusted hazard ratio 0·61, 95% CI 0·40–0·92; p=0·020). |
| Anakinra[65] | Italy | OBS(vs soc) | 45 | HOSP | SEV | At 21 days, survival 90% in the high-dose anakinra group vs 56% in soc group (p=0·009). Mechanical ventilation-free survival 72% in the anakinra group vs 50% in soc group (p=0·15). |
| Anakinra[66] | France | OBS(vs soc) | 22 | HOSP | SEV | 12 anakinra treated patients showed greater clinical improvement and decreased cytokine levels |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | compared to control group with |
| Anakinra[67] | France | OBS(vs soc) | 96 | HOSP | SEV | Admission to the ICU for invasive mechanical ventilation or death occurred in 13 (25%) patients in the anakinra group and 32 (73%) patients in the historical group (hazard ratio [HR] 0·22 [95% CI 0·11–0·41; p<0·0001). |
| TCZ[70] | Italy | RCTPLAC(TCZ vs soc) | 126 | HOSP | SEV | No difference in worsening of clinical state day 28(28.3% TCZ, 27% PLAC) |
| TCZ[71] | U.S.A. | RCTPLAC(TCZvs soc) | 452 | HOSP | SEV,CRIT | No difference in mortality day 28(19.7% TCZ, 19.4% PLAC) |
| TCZ[72] | France | RCT(TCZ vs soc) | 130 | HOSP | SEV | HR for mechanical ventilation or death at day 14 0.58 (90% CrI, 0.30 to 1.09). day 28 mortality 11.1% TCZ, 11.9% soc (adjusted HR, 0.92; 95% CI 0.33-2.53). |
| Dexamethasone[74] | U.K. | RCT(soc) | 6119 | HOSP | MOD,SEV | Dexamethasone reduced 28-day mortality by 35% in patients receiving invasive mechanical ventilation (rate ratio 0.65 [95% CI 0.51 to 0.82]; p<0.001) and by 20% in patients receiving oxygen without invasive mechanical ventilation (rate ratio 0.80 [95% CI 0.70 to 0.92]; p=0.002 |
| Methylprednisolone[75] | Italy | RCT(soc) | 173 | HOSP | SEV | Mehtylprednisoloong group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 plus-or-minus sign 9.0 vs. 17.5 plus-or-minus sign 12.8; p=0.001) |

| | | | | | | |
|---|---|---|---|---|---|---|
| Methylprednisolone[76] | U.S.A. | OBS(soc) | 213 | HOSP | SEV | Early short course of methylprednisolone resulted in decrease need for ICU care, mechanical ventilation and mortality ((34.9% vs 54.3%, P = .005) |
| Methylprednisolone[79] | Brazil | RCT(soc) | 393 | HOSP | MOD,SEV | Overall 28-day mortality was 76/199 (38.2%) in the placebo group vs 72/194 (37.1%) in group which received methylprednisolone short 5 day curse (P=0.629) |
| Corticosteroid[80] | France | OBS(vs no steroid) | 70 | HOSP | MOD,SEV | Reduced risk of intubation -47.1% (95% confidence interval -71.8% to -22.5%). |
| Hydrocortisone[81] | France | RCT(soc) | 149 | HOSP | CRIT | Treatment failure in hydrocortisone group 42% vs 51% placebo |
| Colchicine[82] | Greece | RCT(colchicine vs soc) | 105 | HOSP | MOD,SEV | The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8%in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95%CI, 0.01-0.96; P = .02). |
| Convalescent plasma[83] | China | RCT( soc) | 103 | HOSP | SEV.CRIT | time to clinical improvement at 28 days was 4.9 days shorter (95% CI, −9.33 to −0.54 days) in convalescent plasma group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03). No significant difference in critically ill patients. Mortality 28-day mortality (15.7% convalescent plasma vs 24.0% control ; P = .30) |

| | | | | | | |
|---|---|---|---|---|---|---|
| Convalescent plasma[84] | Italy | OBS | 46 | HOSP | CRIT | 7 day mortality 6.5% |
| Convalescent plasma[85] | Spain | RCT(soc) | 81 | HOSP | MOD,SEV | Mortality 0% for conv plasma group vs 9.3% for control at 29 |
| Convalescent plasma[86] | U.S.A. | OBS | 21,987 | HOSP | MOD,SEV | 7 day mortality 13% |
| Convalescent plasma[87] | U.S.A. | OBS | 3,082 | HOSP | MOD,SEV | adjusted 30-351 day mortality was 30% in patients treated with plasma with low antibody levels (IgG) 4 352 or more days after COVID-19 diagnosis. By contrast 30-day mortality was 20% in 353 patients treated within 3 days of diagnosis with plasma with high antibody levels. |
| Convalescent plasma[88] | India | RCT(soc) | 464 | HOSP | MOD, SEV | Progression to severe disease or all cause mortality at 28 days after enrolment occurred in 44 (19%) participants in the intervention arm and 41 (18%) in the control arm (risk difference 0.008 (95% confidence interval −0.062 to 0.078); risk ratio 1.04, 95% confidence interval 0.71 to 1.54). |
| Famotidine[89] | U.S.A. | OBS(famotidine vs soc) | 1620 | HOSP | MOD,SEV | HR for famotidine for death or intubation 0.43, 95% CI ( 0.21-0.88 ) |
| Ivermectin[90] | U.S.A. | OBS(ivermectin vs soc) | 280 | HOSP | MOD,SEV | lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03) |

| | | | | | | |
|---|---|---|---|---|---|---|
| ChAdOx1-nCoV19[91] | U.K. | RCT (plac) | 1077 | OUTPAT | HEALTHY | 100% spike protein neutralising antibody, spike specific T cell responses |
| mRNA1273[92] | U.S.A. | RCT(plac) | 45 | OUTPAT | HEALTHY | High neutralising antibody titiers, positive Th1-CD4 response |
| Ad5 vectored Covid Vaccine[93] | China | RCT(plac) | 603 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| NVX-Cov2373[94] | Australia | RCT(plac) | 134 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| Coronavac[95] | China | RCT(plac) | 330 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| Ad5 and Ad26 vectored Covid Vaccines[96] | Russia | OBS | 76 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| BTN162b1 and b2[97] | U.S.A. | RCT(plac) | 195 | OUTPAT | HEALTHY | high titer, broad serum neutralizing responses, TH1 phenotype CD4+ T helper cell responses, and strong interferon γ (IFNγ) and interleukin-2 (IL-2) producing CD8+ cytotoxic T-cell responses |

medRxiv preprint doi: https://doi.org/10.1101/2020.05.27.20115238; this version posted November 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

(a)




(b)




Figure 1: THE PHASES OF COVID-19 INFECTION. Asymptomatic viremia typically lasts for 5 days followed by symptoms of an upper respiratory infection. The immune response takes hold over the next week. Pneumonic infiltrates begin to appear. In patients destined for severe infection, a hyperinflammatory reaction takes hold, leading to worsening of pulmonary symptoms, hypoxia, and potentially acute respiratory distress syndrome.

| TRIAL REGISTRATION | COUNTRY | PROJECTED DATE CLOSE ENROLLMENT | SUBJECTS | AGENTS STUDIED | NUMBER SUBJECTS |
|---|---|---|---|---|---|
| CHICTR2000030946 | China | 2020-Apr | HOSP | Anticoagulants, Other | 120 |
| CHICTR2000029898 | China | 2020-Apr | HOSP | HCQ | 100 |
| NCT04282902 | China | 2020-Apr | HOSP | pirfenidone | 294 |
| CHICTR2000030179 | China | 2020-Apr | HOSP | Plasma based therapy, SOC | 100 |
| CHICTR2000030545 | China | 2020-Apr | HOSP | SOC, Herbal tea | 300 |
| NCT04480593 | Brazil | 2020-Aug | HOSP | Alternative therapy, SOC | 120 |
| NCT04335552 | United States | 2020-Aug | HOSP | AZM, HCQ, SOC | 500 |
| NCT04355637 | Spain | 2020-Aug | HOSP | Corticosteroids, SOC | 300 |
| NCT04349592 | Qatar | 2020-Aug | HOSP | HCQ, HCQ + AZM, SOC | 456 |
| NCT04347031 | Russia | 2020-Aug | HOSP | HCQ, Other, TCZ +AZM | 320 |
| NCT04394442 | Saudi Arabia | 2020-Aug | HOSP | HCQ, SOC | 200 |
| NCT04420247 | Brazil | 2020-Aug | HOSP | HCQ, SOC | 100 |
| NCT04476888 | Pakistan | 2020-Aug | HOSP | Plasma based therapy, SOC | 100 |
| NCT04349098 | United States | 2020-Aug | HOSP | selinexor, SOC | 230 |
| NCT04326426 | United States | 2020-Aug | HOSP | Tradipitant (neurokinin 1 inhibitor),SOC | 300 |
| NCT04445272 | Spain | 2020-Aug | HOSP | TCZ | 500 |
| NCT04311697 | United States | 2020-Aug | HOSP | aviptadil Inhaled solution, SOC | 144 |
| NCT04381858 | Mexico | 2020-Aug | HOSP | Igs, Plasma based therapy | 500 |
| NCT04325906 | United States | 2020-Aug | HOSP | Non-invasive respiratory support, Positioning + Non-invasive respiratory support | 346 |
| NCT04394377 | Brazil | 2020-Dec | HOSP | Anticoagulants | 600 |
| NCT04351724 | Austria | 2020-Dec | HOSP | Anticoagulants, HCQ, LPV/r, mAb, RAS blockade, SOC | 500 |
| NCT04452565 | United States | 2020-Dec | HOSP | Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone | 525 |
| NCT04396106 | United States | 2020-Dec | HOSP | AT-527 RNA polymerase inhbitor | 190 |
| NCT04365699 | United States | 2020-Dec | HOSP | AT001, SOC | 500 |
| NCT04321096 | Denmark | 2020-Dec | HOSP | Camostat, SOC | 580 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04392531 | Spain | 2020-Dec | HOSP | Cyclosporine, SOC | 120 |
| NCT04397718 | United States | 2020-Dec | HOSP | Hormone therapy, SOC | 198 |
| NCT04421027 | United States | 2020-Dec | HOSP | JAKi, SOC | 600 |
| NCT04469114 | Israel | 2020-Dec | HOSP | JAKi, SOC | 260 |
| NCT04347239 | United States | 2020-Dec | HOSP | Leronlimab, SOC | 390 |
| NCT04376684 | United States | 2020-Dec | HOSP | mAb, SOC | 800 |
| NCT04401202 | Saudi Arabia | 2020-Dec | HOSP | Nigella sativa, SOC | 200 |
| NCT04432298 | United States | 2020-Dec | HOSP | pamrevlumab (Ab to connective tisue growth factor), SOC | 130 |
| NCT04433546 | United States | 2020-Dec | HOSP | pemziviptadil, SOC | 210 |
| NCT04392232 | United States | 2020-Dec | HOSP | Plasma based therapy | 100 |
| NCT04400058 | United States | 2020-Dec | HOSP | Plasma based therapy, SOC | 208 |
| NCT04359810 | United States | 2020-Dec | HOSP | Plasma based therapy, SOC | 105 |
| NCT04424797 | United States | 2020-Dec | HOSP | Positioning | 100 |
| NCT04391140 | Spain | 2020-Dec | HOSP | Positioning + Respiratory support, Respiratory support | 248 |
| NCT04402879 | Canada | 2020-Dec | HOSP | Positioning, SOC | 596 |
| NCT04365257 | United States | 2020-Dec | HOSP | prazosin, SOC | 220 |
| NCT04412356 | Sweden | 2020-Dec | HOSP | Procedure | 180 |
| NCT04479358 | United States | 2020-Dec | HOSP | SOC, TCZ | 332 |
| NCT04317092 | Italy | 2020-Dec | HOSP | TCZ | 400 |
| NCT04433910 | Germany | 2020-Dec | HOSP | Plasma based therapy, SOC | 106 |
| NCT04433910 | Germany | 2020-Dec | HOSP | Plasma based therapy, SOC | 106 |
| NCT04406389 | United States | 2020-Dec | HOSP | Anticoagulants | 186 |
| NCT04344730 | France | 2020-Dec | HOSP | Dexamethasone with or without respiratory suppport, SOC | 550 |
| NCT04480424 | United States | 2020-Dec | HOSP | IvIg, SOC | 100 |
| NCT04443881 | Spain | 2020-Dec | HOSP | Anakinra, SOC | 180 |
| NCT04485429 | Brazil | 2020-Dec | HOSP | Anticoagulants, Anticoagulants + Corticosteroids, Corticosteroids, SOC | 268 |
| NCT04466670 | Brazil | 2020-Dec | HOSP | Anticoagulants, Antihypertensive | 310 |
| NCT04409509 | United States | 2020-Dec | HOSP | FX12 antbody, SOC | 124 |
| NCT04535063 | Argentina | 2020-Dec | HOSP | Plasma based therapy | 200 |
| NCT04336462 | China | 2020-Feb | HOSP | Hydrogen, oxygen, SOC | 100 |

| | | | | | |
|---|---|---|---|---|---|
| CHICTR2000032367 | China | 2020-Jul | HOSP | Exercise, SOC | 186 |
| NCT04355897 | United States | 2020-Jul | HOSP | Plasma based therapy | 100 |
| NCT04342182 | Netherlands | 2020-Jul | HOSP | Plasma based therapy, SOC | 426 |
| NCT04345523 | Spain | 2020-Jul | HOSP | Plasma based therapy, SOC | 278 |
| NCT04468646 | Pakistan | 2020-Jul | HOSP | Neurokinin 1 receptor agonist, SOC | 100 |
| CHICTR2000030333 | China | 2020-Jul | HOSP | pirfenidone, SOC | 292 |
| NCT04459325 | Russia | 2020-Jul | HOSP | dornase, alfa | 100 |
| NCT04322344 | Italy | 2020-Jun | HOSP | Alternative therapy, SOC | 120 |
| NCT04305106 | China | 2020-Jun | HOSP | Bevacizumab, SOC | 140 |
| NCT04375202 | Italy | 2020-Jun | HOSP | Colchicine, SOC | 308 |
| NCT04347980 | France | 2020-Jun | HOSP | Dexamethasone + HCQ, HCQ | 122 |
| CHICTR2000029777 | China | 2020-Jun | HOSP | SOC, Herbal tea | 160 |
| CHICTR2000029781 | China | 2020-Jun | HOSP | SOC, Herbal tea | 160 |
| CHICTR2000034796 | China | 2020-Mar | HOSP | Anticoagulants, SOC | 160 |
| NCT04329195 | France | 2020-May | HOSP | Antihypertensive | 554 |
| NCT04329650 | Spain | 2020-May | HOSP | Corticosteroids, Siltuximab | 200 |
| CHICTR2000030894 | China | 2020-May | HOSP | FPV, FPV + TCZ, TCZ | 150 |
| CHICTR2000029603 | China | 2020-May | HOSP | LPV/r, ASC09/r | 160 |
| CHICTR2000030001 | China | 2020-May | HOSP | LPV/r, Emcetrabine/r, SOC | 240 |
| CHICTR2000029763 | China | 2020-May | HOSP | SOC, Heral Tea | 408 |
| CHICTR2000029755 | China | 2020-May | HOSP | SOC, Herbal tea | 120 |
| CHICTR2000029765 | China | 2020-May | HOSP | SOC, TCZ | 188 |
| CHICTR2000030779 | China | 2020-May | HOSP | ulinastatin, SOC | 100 |
| NCT04310228 | China | 2020-May | HOSP | FPV, FPV + TCZ, TCZ | 150 |
| NCT04346199 | Argentina | 2020-Nov | HOSP | Acalabrutinib, SOC | 140 |
| NCT04444700 | Brazil | 2020-Nov | HOSP | Anticoagulants, SOC | 462 |
| NCT04362085 | Canada | 2020-Nov | HOSP | Anticoagulants, SOC | 462 |
| NCT04344288 | France | 2020-Nov | HOSP | Corticosteroids, SOC | 304 |
| NCT04382053 | Brazil | 2020-Nov | HOSP | DFV890, SOC | 120 |
| NCT04358081 | United States | 2020-Nov | HOSP | HCQ, HCQ + AZM, SOC | 444 |
| NCT04362137 | United States | 2020-Nov | HOSP | JAKi, SOC | 402 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04511819 | United States | 2020-Nov | HOSP | Losmapimod, SOC | 410 |
| NCT04448756 | United States | 2020-Nov | HOSP | M5049 (toll like receptor inhibitor), Other | 150 |
| NCT04441385 | Spain | 2020-Nov | HOSP | Maraviroc, SOC | 200 |
| NCT04463420 | Iran | 2020-Nov | HOSP | PHR160 asal spray+ HCQ + NSAIDs + AZM | 224 |
| NCT04388410 | Mexico | 2020-Nov | HOSP | Plasma based therapy, SOC | 410 |
| NCT04495101 | Spain | 2020-Nov | HOSP | prolastin (proteinase inhibitor), SOC | 100 |
| NCT04449718 | Brazil | 2020-Nov | HOSP | SOC, Vitamin D | 200 |
| NCT04386850 | Iran | 2020-Nov | HOSP | SOC, Vitamins | 1500 |
| NCT04384900 | Denmark | 2020-Nov | HOSP | Positioning | 150 |
| NCT04400890 | United States | 2020-Nov | HOSP | Plant polyphenols | 200 |
| NCT04477655 | Mexico | 2020-Nov | HOSP | Positioning, SOC | 200 |
| NCT04427098 | Italy | 2020-Oct | HOSP | Anticoagulants | 300 |
| NCT04530578 | Argentina | 2020-Oct | HOSP | Anticoagulants | 200 |
| NCT04486508 | Iran | 2020-Oct | HOSP | Anticoagulants, SOC, Statins | 600 |
| NCT04470622 | United States | 2020-Oct | HOSP | Aprepitant (antiemetic), SOC | 100 |
| NCT04340557 | United States | 2020-Oct | HOSP | ARB, SOC | 200 |
| NCT04364893 | Brazil | 2020-Oct | HOSP | ARBs + ACEi, SOC | 700 |
| NCT04350320 | Spain | 2020-Oct | HOSP | Colchicine, SOC | 102 |
| NCT04322396 | Denmark | 2020-Oct | HOSP | HCQ + AZM, SOC | 226 |
| NCT04348656 | United States | 2020-Oct | HOSP | Plasma based therapy, SOC | 1200 |
| NCT04385043 | Italy | 2020-Oct | HOSP | Plasma based therapy, SOC | 400 |
| NCT04395144 | Canada | 2020-Oct | HOSP | Positioning, SOC | 346 |
| NCT04335071 | Switzerland | 2020-Oct | HOSP | SOC, TCZ | 100 |
| NCT04385836 | Saudi Arabia | 2020-Sep | HOSP | alpha1 antitrypsin, SOC | 150 |
| NCT04341116 | United States | 2020-Sep | HOSP | anti GM-CSF, SOC | 144 |
| NCT04335136 | Austria | 2020-Sep | HOSP | Antihypertensive, SOC | 200 |
| NCT04386616 | United States | 2020-Sep | HOSP | astegolimab, SOC | 300 |
| NCT04452435 | India | 2020-Sep | HOSP | C21, SOC | 100 |
| NCT04451174 | Chile | 2020-Sep | HOSP | Corticosteroids, SOC | 184 |
| NCT04332094 | Spain | 2020-Sep | HOSP | HCQ + AZM, TCZ + AZM + HCQ | 276 |
| NCT04403100 | Brazil | 2020-Sep | HOSP | HCQ, HCQ + LPV/r, LPV/r, SOC | 1968 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04370262 | United States | 2020-Sep | HOSP | HCQ, HCQ + Other, SOC | 942 |
| NCT04351152 | United States | 2020-Sep | HOSP | Lenzilumab, SOC | 300 |
| NCT04334629 | United Kingdom | 2020-Sep | HOSP | NSAIDs, SOC | 230 |
| NCT04374526 | Italy | 2020-Sep | HOSP | Plasma based therapy, SOC | 182 |
| CHICTR2000030522 | China | 2020-Sep | HOSP | SOC, Herbal tea | 100 |
| NCT04379271 | Bulgaria | 2020-Sep | HOSP | vidofludimus (pyrimidine synthesis inhibitor), SC | 230 |
| NCT04377620 | United States | 2020-Sep | HOSP | JAKi, SOC | 500 |
| NCT04445935 | Qatar | 2020-Sep | HOSP | Anticoagulants, SOC | 100 |
| NCT04359277 | United States | 2021-Apr | HOSP | Anticoagulants | 1000 |
| NCT04360824 | United States | 2021-Apr | HOSP | Anticoagulants | 170 |
| NCT04360824 | United States | 2021-Apr | HOSP | Anticoagulants | 170 |
| NCT04312009 | United States | 2021-Apr | HOSP | ARBs | 200 |
| NCT04381377 | Russia | 2021-Apr | HOSP | Azoximer bromide, SOC | 394 |
| NCT04367168 | Mexico | 2021-Apr | HOSP | Colchicine, SOC | 174 |
| IRCT20200517047485N1 | Iran | 2021-Apr | HOSP | HCQ + Atazanavir/ritonavir, HCQ + LPV/r | 108 |
| NCT04328493 | Vietnam | 2021-Apr | HOSP | HCQ, SOC | 250 |
| NCT04328493 | Vietnam | 2021-Apr | HOSP | HCQ, SOC | 250 |
| NCT04320056 | Canada | 2021-Apr | HOSP | Non-invasive respiratory support, SOC | 216 |
| NCT04344431 | France | 2021-Apr | HOSP | Non-invasive respiratory support, SOC | 100 |
| NCT04362176 | United States | 2021-Apr | HOSP | Plasma based therapy, SOC | 500 |
| NCT04359797 | United States | 2021-Apr | HOSP | Positioning | 300 |
| NCT04346615 | United States | 2021-Apr | HOSP | Zavegepant (CGRP agonist), SOC | 120 |
| NCT04352751 | Pakistan | 2021-Apr | HOSP | Plasma based therapy | 2000 |
| IRCT20200414047072N1 | Iran | 2021-Apr | HOSP | Plasma based therapy | 357 |
| NCT04389710 | United States | 2021-Apr | HOSP | Plasma based therapy | 100 |
| NCT04355143 | United States | 2021-Apr | HOSP | Colchicine, SOC | 150 |
| NCT04387760 | Bahrain | 2021-Apr | HOSP | FPV, HCQ, SOC | 150 |
| CHICTR2000029739 | China | 2021-Aug | HOSP | Non-invasive respiratory support | 440 |
| NCT04513158 | United States | 2021-Aug | HOSP | Plasma based therapy | 100 |
| NCT04345692 | United States | 2021-Dec | HOSP | HCQ, SOC | 350 |
| NCT04381936 | United Kingdom | 2021-Dec | HOSP | RECOVERY TRIAL Conv plasma vs TCZ vs Monoclonal Abs | 15000 |

| | | | | | |
|---|---|---|---|---|---|
| CHICTR2000031430 | China | 2021-Dec | HOSP | SOC, Stem cells | 200 |
| NCT04412772 | United States | 2021-Dec | HOSP | SOC, TCZ | 300 |
| NCT04339816 | Czechia | 2021-Dec | HOSP | HCQ, | 240 |
| NCT04447469 | United States | 2021-Feb | HOSP | Antibody to GM-CSF | 573 |
| NCT04390594 | Senegal | 2021-Feb | HOSP | HCQ, HCQ + AZM | 186 |
| NCT04477993 | Brazil | 2021-Feb | HOSP | JAKi, SOC | 200 |
| NCT04393246 | United Kingdom | 2021-Feb | HOSP | Other, SGLT2 + Other, SOC | 1407 |
| CHICTR2000029757 | China | 2021-Feb | HOSP | Plasma based therapy, SOC | 200 |
| NCT04348383 | Spain | 2021-Jan | HOSP | Antithrombotics, SOC | 120 |
| NCT04338958 | Germany | 2021-Jan | HOSP | JAKi | 200 |
| NCT04426695 | United States | 2021-Jan | HOSP | mAB | 2970 |
| NCT04460183 | United Kingdom | 2021-Jan | HOSP | Non-invasive respiratory support, SOC | 300 |
| CHICTR2000029806 | China | 2021-Jan | HOSP | PD1, thymosin, SOC | 120 |
| NCT04439071 | United States | 2021-Jan | HOSP | PTC299 (DDODH inhibitor), SOC | 380 |
| NCT04363814 | Dominican Republic | 2021-Jul | HOSP | BAKTEC-R bacterial identification, SOC | 100 |
| NCT04514627 | United States | 2021-Jul | HOSP | Other, SOC | 100 |
| NCT04401423 | United States | 2021-Jun | HOSP | Antihypertensive, SOC | 100 |
| NCT04359953 | France | 2021-Jun | HOSP | ARBs, AZM, HCQ | 1600 |
| NCT04414631 | Switzerland | 2021-Jun | HOSP | Conestat alfa (C1esterase inhibitor), SOC | 120 |
| NCT04345289 | Denmark | 2021-Jun | HOSP | Conv Plasma | 1100 |
| NCT04432272 | United States | 2021-Jun | HOSP | Plasma based therapy | 500 |
| NCT04418518 | United States | 2021-Jun | HOSP | Plasma-based therapy, SOC | 1200 |
| NCT04364763 | United States | 2021-Jun | HOSP | RBT-9 (antiviral), SOC | 252 |
| NCT04322773 | Denmark | 2021-Jun | HOSP | Sarilumab, SOC, TCZ | 200 |
| NCT04323514 | Italy | 2021-Mar | HOSP | Axcorbic Acid | 500 |
| IRCT20170731035423N2 | Iran | 2021-Mar | HOSP | BCC1 and Hep S, SOC | 120 |
| NCT04420299 | Spain | 2021-Mar | HOSP | Bemiparin (low molecular wt heparin), SOC | 120 |
| NCT04351763 | Poland | 2021-Mar | HOSP | CCB, Other, SOC | 804 |
| NCT04476979 | France | 2021-Mar | HOSP | Corticosteroids, TCZ + Corticosteroids | 120 |
| NCT04373733 | United Kingdom | 2021-Mar | HOSP | FPV, HCQ + AZM + Zinc, SOC | 450 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04342221 | Germany | 2021-Mar | HOSP | HCQ, SOC | 220 |
| IRCT20170922036314N4 | Iran | 2021-Mar | HOSP | Psychological therapy, SOC | 112 |
| NCT04380961 | United States | 2021-Mar | HOSP | sirukamab (IL6 inhibitor), SOC | 270 |
| NCT04306393 | United States | 2021-Mar | HOSP | Non-invasive respiratory support, SOC | 200 |
| NCT04306393 | United States | 2021-Mar | HOSP | Non-invasive respiratory support, SOC | 200 |
| NCT04306393 | United States | 2021-Mar | HOSP | Non-invasive respiratory support, SOC | 200 |
| NCT04376034 | United States | 2021-Mar | HOSP | Plasma based therapy, SOC | 240 |
| NCT04366050 | United States | 2021-May | HOSP | ACEi, SOC | 560 |
| NCT04379492 | United States | 2021-May | HOSP | HCQ, SOC | 120 |
| NCT04333420 | Netherlands | 2021-May | HOSP | IFN, SOC | 390 |
| NCT04390464 | United Kingdom | 2021-May | HOSP | JAKi, mAb, SOC | 1167 |
| NCT04365985 | United States | 2021-May | HOSP | Opiate antagonists, Opiate antagonists + Anesthetic, SOC | 500 |
| NCT04516915 | United Kingdom | 2021-May | HOSP | Oseltamivir, vidoflidimus + Oseltamivir | 120 |
| IRCT20200501047258N1 | Iran | 2021-May | HOSP | Plasma based therapy, SOC | 120 |
| NCT04374539 | Spain | 2021-May | HOSP | Plasma based therapy, SOC | 116 |
| NCT04367077 | United States | 2021-Sep | HOSP | SOC, Stem cells | 400 |
| NCT04415086 | Brazil | 2022-Apr | HOSP | Plasma-based therapy, SOC | 120 |
| NCT04478071 | United States | 2022-Aug | HOSP | Vadadustat(hypoxia inducible factor), SOC | 300 |
| NCT04321993 | Canada | 2022-Feb | HOSP | HCQ, JAKi, LPV/r, Sarilumab | 800 |
| NCT04394416 | United States | 2022-Jun | HOSP | Imatinib, SOC | 204 |
| NCT04330690 | Canada | 2022-Mar | HOSP | LPV/r, SOC | 2900 |
| NCT04354831 | United States | 2022-May | HOSP | Plasma based therapy | 131 |
| NCT04412486 | United States | 2022-May | HOSP | Plasma based therapy | 100 |
| NCT04470544 | United States | 2022-Sep | HOSP | Camostat, SOC | 264 |
| NCT04364737 | United States | 2023-Jan | HOSP | Plasma based therapy, SOC | 300 |
| NCT04276896 | China | 2023-Jul | HOSP | LV-SMENP-DC Vaccine | 100 |
| NCT04415060 | Canada | 2023-Jun | HOSP | Anesthetic, SOC | 752 |
| NCT04315948 | Austria | 2023-Mar | HOSP | HCQ, LPV/r, LPV/r + IFN, Remdesivir, SOC | 3100 |
| NCT04435353 | Kazakhstan | NA | HOSP | Alternative therapy | 200 |
| CTRI/2020/05/025434 | India | NA | HOSP | Alternative therapy | 135 |
| CTRI/2020/06/025977 | India | NA | HOSP | Alternative therapy, SOC | 120 |

| | | | | | |
|---|---|---|---|---|---|
| CTRI/2020/06/025590 | India | NA | HOSP | Alternative therapy, SOC | 120 |
| CTRI/2020/04/024883 | India | NA | HOSP | Alternative therapy, SOC | 112 |
| NCT04347226 | United States | NA | HOSP | anti-IL8, SOC | 138 |
| NCT04401293 | United States | NA | HOSP | Anticoagulants | 308 |
| 2020-001972-13 | Italy | NA | HOSP | Anticoagulants | 300 |
| NCT04508439 | Mexico | NA | HOSP | Anticoagulants | 130 |
| NCT04372589 | United States | NA | HOSP | Anticoagulants, SOC | 3000 |
| NCT04389840 | United States | NA | HOSP | Anticoagulants, SOC | 524 |
| ACTRN12620000517976 | Australia | NA | HOSP | Anticoagulants, SOC | 206 |
| NCT04493359 | Brazil | NA | HOSP | Antihypertensive | 240 |
| NCT04328012 | United States | NA | HOSP | ARBs, HCQ, LPV/r, SOC | 4000 |
| ISRCTN48734830 | Sweden | NA | HOSP | ARBs, SOC | 750 |
| NCT04335786 | Netherlands | NA | HOSP | ARBs, SOC | 651 |
| CTRI/2020/05/025319 | India | NA | HOSP | ARBs, SOC | 186 |
| CTRI/2020/05/025271 | India | NA | HOSP | BCG, SOC | 480 |
| NCT04334460 | United States | NA | HOSP | BLD2660 (protese inhibitor), SOC | 120 |
| CTRI/2020/06/026192 | India | NA | HOSP | C21, SOC | 100 |
| NCT04362813 | United States | NA | HOSP | Canakinumab, SOC | 450 |
| NCT04328480 | Argentina | NA | HOSP | Colchicine, SOC | 2500 |
| NCT04381364 | Sweden | NA | HOSP | Corticosteroids, SOC | 446 |
| NCT04331054 | France | NA | HOSP | Corticosteroids, SOC | 436 |
| NCT04323592 | Italy | NA | HOSP | Corticosteroids, SOC | 104 |
| NCT04345614 | United States | NA | HOSP | CRAC channel inhibitor, SOC | 400 |
| NCT04395105 | Argentina | NA | HOSP | Dexamethasone, SOC | 284 |
| NCT04424901 | United States | NA | HOSP | Dipyridamole, SOC | 100 |
| 2020-001643-13 | United Kingdom | NA | HOSP | DPP1 inhibitor, SOC | 300 |
| ISRCTN30564012 | United Kingdom | NA | HOSP | DPP1 inhibitor, SOC | 300 |
| NCT04494984 | Argentina | NA | HOSP | Equine hyperimmune serum, SOC | 242 |
| JPRN-JRCTS031190226 | Japan | NA | HOSP | FPV | 100 |
| NCT04411433 | Turkey | NA | HOSP | FPV, FPV + AZM, HCQ, HCQ + AZM, HCQ + FPV | 1000 |
| CTRI/2020/06/025957 | India | NA | HOSP | FPV, FPV + Umifenovir | 158 |

| | | | | | |
|---|---|---|---|---|---|
| 2020-001904-41 | United Kingdom | NA | HOSP | FPV, SOC | 302 |
| CTRI/2020/06/025704 | India | NA | HOSP | HCQ + AZM, HCQ + Other + AZM | 120 |
| NCT04355052 | Israel | NA | HOSP | HCQ + AZM, HCQ + Other, SOC | 250 |
| NCT04392973 | Saudi Arabia | NA | HOSP | HCQ + FPV, SOC | 520 |
| NCT04346147 | Spain | NA | HOSP | HCQ + Imatinib, HCQ + JAKi, HCQ + LPV/r | 165 |
| 2020-002035-30 | Italy | NA | HOSP | HCQ, HCQ + JAKi | 116 |
| 2020-000936-23 | Austria | NA | HOSP | HCQ, LPV/r, Remdesivir | 3100 |
| PACTR202004801273802 | Nigeria | NA | HOSP | HCQ, SOC | 800 |
| ISRCTN88057279 | United Kingdom | NA | HOSP | HCQ, SOC | 500 |
| NCT04459676 | Brazil | NA | HOSP | heptocyte growth factor, SOC | 100 |
| NCT04382924 | United States | NA | HOSP | Ifenprodil, SOC | 682 |
| 2020-001023-14 | United Kingdom | NA | HOSP | IFN, SOC | 400 |
| NL8491 | Netherlands | NA | HOSP | imatinib, SOC | 386 |
| CTRI/2020/04/024806 | India | NA | HOSP | Imatinib, SOC | 100 |
| 2020-001750-22 | United Kingdom | NA | HOSP | Immunomodulators, JAKi, SOC | 186 |
| NCT04402866 | United Kingdom | NA | HOSP | JAK1,SOC | 159 |
| NCT04373044 | United States | NA | HOSP | JAKi, HCQ, SOC | 144 |
| ISRCTN11188345 | United Kingdom | NA | HOSP | JAKi, mAb, SOC | 375 |
| NCT04404361 | United States | NA | HOSP | JAKi, SOC | 358 |
| 2020-001807-18 | Finland | NA | HOSP | JAKi, SOC | 159 |
| 2020-001759-42 | Argentina | NA | HOSP | mAb, SOC | 800 |
| NCT04382651 | United States | NA | HOSP | MAS825, SOC | 120 |
| NCT04374032 | Bosnia & Herzegovina | NA | HOSP | metenkefalin + tridecactide,SOC | 120 |
| ISRCTN40580903 | United Kingdom | NA | HOSP | Mylotarg, Infliximab, Namilumab, SOC | 588 |
| 2020-001236-10 | Netherlands | NA | HOSP | NA | 304 |
| NCT04395807 | Sweden | NA | HOSP | Non-invasive respiratory support | 120 |
| NCT04467840 | Israel | NA | HOSP | opaganib (sphingosine kinase), SOC | 270 |
| 2020-001805-21 | United Kingdom | NA | HOSP | Oseltamivir, Oseltamivir + Other | 120 |
| 2020-002229-27 | United Kingdom | NA | HOSP | Other, Other + SGLT2, SOC | 1407 |
| ISRCTN60069084 | Oman | NA | HOSP | Other, SOC | 1180 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04472728 | United States | NA | HOSP | Other, SOC | 310 |
| NCT04408040 | United States | NA | HOSP | Plasma based therapy | 700 |
| NCT04393727 | Italy | NA | HOSP | Plasma based therapy | 126 |
| NCT04344535 | United States | NA | HOSP | Plasma based therapy, SOC | 500 |
| NCT04429854 | Belgium | NA | HOSP | Plasma based therapy, SOC | 483 |
| NL8633 | Netherlands | NA | HOSP | Plasma based therapy, SOC | 430 |
| NCT04479163 | Argentina | NA | HOSP | Plasma based therapy, SOC | 210 |
| ISRCTN85216856 | Ecuador | NA | HOSP | Plasma based therapy, SOC | 200 |
| NCT04358939 | France | NA | HOSP | Positioning | 248 |
| NCT04366856 | France | NA | HOSP | Positioning, SOC | 500 |
| NCT04383613 | Canada | NA | HOSP | Positioning, SOC | 350 |
| ISRCTN54917435 | Sweden | NA | HOSP | Positioning, SOC | 240 |
| NCT04343963 | Mexico | NA | HOSP | Pyridostigmine, SOC | 436 |
| 2020-001497-30 | France | NA | HOSP | ravilizumab(complement inhibitor), SOC | 270 |
| 2020-001786-36 | Belgium | NA | HOSP | Recombinant interleukin 7, SOC | 200 |
| 2020-001573-78 | United States | NA | HOSP | Recombinant interleukin 7, SOC | 200 |
| 2020-001453-49 | France | NA | HOSP | Remdesivir | 2500 |
| NCT04409262 | United States | NA | HOSP | Remdesivir, Remdesivir + TCZ | 450 |
| 2020-001052-18 | Denmark | NA | HOSP | Remdesivir, SOC | 440 |
| ISRCTN13035264 | Denmark | NA | HOSP | Remdesivir, SOC | 400 |
| NCT04359901 | United States | NA | HOSP | Sarilumab, SOC | 120 |
| 2020-001473-79 | Italy | NA | HOSP | SGLT2, SOC | 900 |
| NCT04389450 | United States | NA | HOSP | SOC, Stem cells | 140 |
| CHICTR2000029990 | China | NA | HOSP | SOC, Stem cells | 120 |
| NCT04366271 | Spain | NA | HOSP | SOC, Stem cells | 106 |
| NCT04393415 | Egypt | NA | HOSP | SOC, Stem cells | 100 |
| CTRI/2020/05/025369 | India | NA | HOSP | SOC, TCZ | 180 |
| NCT04411446 | Argentina | NA | HOSP | SOC, Vitamins | 1265 |
| ACTRN12620000454976 | Australia | NA | HOSP | SOC, Zinc | 160 |
| 2020-002120-37 | France | NA | HOSP | sodium nitrite, SOC | 300 |
| 2020-002060-31 | Czechia | NA | HOSP | SOLIDARITY TRIAL | 100000 |

| | | | | | |
|---|---|---|---|---|---|
| ISRCTN83971151 | Argentina | NA | HOSP | SOLIDARITY TRIAL | 10000 |
| CTRI/2020/04/024773 | Argentina | NA | HOSP | SOLIDARITY TRIAL | 7000 |
| NCT04417257 | United States | NA | HOSP | tenretidine, SOC | 240 |
| NCT04419623 | United States | NA | HOSP | TL-895 (tyrosine kinase inhibitor), SOC | 146 |
| NL8504 | Netherlands | NA | HOSP | TCZ | 354 |
| NCT04378920 | France | NA | HOSP | trancrocetin (NMDA inhibitor), SOC | 180 |
| 2020-001264-28 | Bulgaria | NA | HOSP | vidofludimus (pyrimidine synthesis inhibitor), SC | 200 |
| NCT04453384 | France | NA | HOSP | XAV19( spike protein antibody), SOC | 368 |
| NCT04373707 | France | NA | HOSP | Anticoagulants | 602 |
| NCT04345848 | Switzerland | NA | HOSP | Anticoagulants | 200 |
| CTRI/2020/06/026193 | India | NA | HOSP | HCQ +/- AZM, HCQ + Lithium +/- AZM | 100 |
| NCT04321616 | Norway | NA | HOSP | HCQ, Remdesivir, SOC | 700 |
| 2020-001754-21 | France | NA | HOSP | JAKi + TCZ or Anakinra, SOC, TCZ or Anakinra | 150 |
| NCT04346797 | France | NA | HOSP | mAb, SOC | 120 |
| NCT04347681 | Saudi Arabia | NA | HOSP | Plasma based therapy | 575 |
| NCT04474340 | Kuwait | NA | HOSP | Plasma based therapy, SOC | 300 |
| NCT04361253 | United States | NA | HOSP | Plasma based therapy, SOC | 220 |
| NCT04401150 | Canada | NA | HOSP | SOC, Vitamins | 800 |
| NCT04498936 | Egypt | NA | HOSP | Sofosbuvir/Ledipasvir and Nitazoxanide, DAA, SOC | 240 |
| NCT04363853 | Mexico | NA | HOSP | TCZ | 200 |
| 2020-001644-25 | Argentina | NA | HOSP | Acalabrutinib, SOC | 177 |
| NCT04367831 | United States | NA | HOSP | Anticoagulants | 100 |
| NCT04409834 | United States | NA | HOSP | Anticoagulants, Anticoagulants + Antiplatelets | 750 |
| 2020-001921-30 | Italy | NA | HOSP | Anticoagulants, Corticosteroids + Anticoagulants | 200 |
| NCT04371367 | France | NA | HOSP | Avdirolimab (anti C5 antibody), SOC | 108 |
| NCT04355364 | France | NA | HOSP | dornase alfa, SOC | 100 |
| NCT04432051 | Turkey | NA | HOSP | Monitoring, SOC | 100 |
| NCT04358003 | United States | NA | HOSP | Plasma based therapy | 2000 |
| NCT04350580 | France | NA | HOSP | Polyvalent Immunoglbulin, SOC | 138 |
| NCT04347941 | Ireland | NA | HOSP | Positioning, SOC | 200 |
| JPRN-JRCT2031200126 | United States | NA | HOSP | ravilizumab (complement inhibitor), SOC | 270 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04371393 | United States | NA | HOSP | SOC, Stem cells | 300 |
| DRKS00021238 | Germany | NA | HOSP | SOC, TCZ | 200 |
| NCT04264533 | China | NA | HOSP | SOC, Vitamin C | 140 |
| NCT04364009 | France | NA | HOSP | Anakinra, SOC | 240 |
| JPRN-JRCTS031200026 | Japan | NA | HOSP | Anticoagulants, FPV | 160 |
| PACTR202007606032743 | Egypt | NA | HOSP | Anticoagulants, SOC | 100 |
| NCT04263402 | China | NA | HOSP | Corticosteroids | 100 |
| KCT0005105 | South Korea | NA | HOSP | Corticosteroids, HCQ + Corticosteroids, SOC | 141 |
| NCT04361474 | France | NA | HOSP | Corticosteroids, SOC | 120 |
| NCT04530409 | Egypt | NA | HOSP | Dexamethasone | 450 |
| NCT04384588 | Chile | NA | HOSP | Plasma based therapy | 100 |
| CTRI/2020/06/025803 | India | NA | HOSP | Plasma based therapy, SOC | 400 |
| NCT04425915 | India | NA | HOSP | Plasma based therapy, SOC | 400 |
| NCT04345419 | Egypt | NA | HOSP | remdesivir, chloroquine, SOC | 120 |
| 2020-001390-76 | Italy | NA | HOSP | Sarilumab, SOC | 171 |
| NCT04486144 | United States | NA | OUTPAT | Alternative therapy, SOC | 100 |
| CHICTR2000029899 | China | 2020-Apr | OUTPAT | HCQ | 100 |
| NCT04438850 | Italy | 2020-Aug | OUTPAT | Ivermectin, SOC | 102 |
| NCT04337918 | Canada | 2020-Aug | OUTPAT | Non-invasive respiratory support | 200 |
| NCT04369365 | Austria | 2020-Aug | OUTPAT | AZM, SOC | 200 |
| CHICTR2000029601 | China | 2020-Aug | OUTPAT | Education, Education + Herbal tea | 400 |
| NCT04466540 | Brazil | 2020-Aug | OUTPAT | HCQ, SOC | 1300 |
| NCT04466540 | Brazil | 2020-Aug | OUTPAT | HCQ, SOC | 1300 |
| NCT04438057 | United States | 2020-Aug | OUTPAT | Plasma based therapy, SOC | 150 |
| NCT04406246 | Mexico | 2020-Dec | OUTPAT | Niazoxanide, SOC | 150 |
| NCT04356495 | France | 2020-Dec | OUTPAT | Antihypertensive, FPV, HCQ, Other, SOC | 634 |
| NCT04532931 | South Africa | 2020-Dec | OUTPAT | Antimalarial, DAA, FPV + Antivirals, SOC | 250 |
| NCT04322682 | United States | 2020-Dec | OUTPAT | Colchicine, SOC | 6000 |
| NCT04322565 | Italy | 2020-Dec | OUTPAT | Colchicine, SOC | 310 |
| NCT04334382 | United States | 2020-Dec | OUTPAT | HCQ vs AZM | 1550 |
| CHICTR2000029741 | China | 2020-Dec | OUTPAT | HCQ, LPV/r | 112 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04372628 | United States | 2020-Dec | OUTPAT | HCQ, LPV/r, SOC | 600 |
| NCT04529525 | Argentina | 2020-Dec | OUTPAT | Ivermectin, SOC | 500 |
| NCT04446377 | United States | 2020-Dec | OUTPAT | LAM002 (lysosome activator), SOC | 142 |
| NCT04425629 | United States | 2020-Dec | OUTPAT | mAB, SOC | 2104 |
| NCT04342728 | United States | 2020-Dec | OUTPAT | SOC, Ascorbic Acid, Ascorbic Acid + Zinc, Zinc | 520 |
| CHICTR2000029621 | China | 2020-Dec | OUTPAT | SOC, Umifenovir | 380 |
| NCT04338074 | United States | 2020-Dec | OUTPAT | tranexamic acid | 100 |
| NCT04464408 | Saudi Arabia | 2020-Dec | OUTPAT | FPV, SOC | 576 |
| CHICTR2000029780 | China | 2020-Jun | OUTPAT | SOC, Herbal tea | 160 |
| NCT04346667 | Pakistan | 2020-May | OUTPAT | HCQ, SOC | 400 |
| NCT04351191 | Pakistan | 2020-May | OUTPAT | HCQ, SOC | 400 |
| NCT04345991 | France | 2020-May | OUTPAT | Plasma based therapy, SOC | 120 |
| NCT04416399 | United Kingdom | 2020-Nov | OUTPAT | Corticosteroids, SOC | 478 |
| NCT04517422 | Mexico | 2020-Nov | OUTPAT | Nutrition, SOC | 300 |
| NCT04486313 | United States | 2020-Oct | OUTPAT | Antivirals + Vitamins, Vitamins | 800 |
| NCT04363827 | Italy | 2020-Sep | OUTPAT | HCQ, SOC | 2300 |
| NCT04332107 | United States | 2020-Sep | OUTPAT | AZM, SOC | 2271 |
| NCT04381962 | United Kingdom | 2020-Sep | OUTPAT | AZM, SOC | 800 |
| NCT04416334 | Spain | 2020-Sep | OUTPAT | Colchicine, SOC | 1028 |
| NCT04377711 | United States | 2020-Sep | OUTPAT | Corticosteroids, SOC | 400 |
| NCT04370782 | United States | 2020-Sep | OUTPAT | HCQ + AZM+ Zinc, HCQ + Zinc + Antibiotics | 750 |
| NCT04331600 | Poland | 2020-Sep | OUTPAT | HCQ, SOC | 400 |
| NCT04518410 | United States | 2020-Sep | OUTPAT | Other, SOC | 2000 |
| CHICTR2000033057 | China | 2020-Sep | OUTPAT | Rehabilitation | 160 |
| NCT04427501 | United States | 2020-Sep | OUTPAT | mAB, SOC | 800 |
| NCT04329923 | United States | 2021-Apr | OUTPAT | HCQ, SOC | 400 |
| NCT04390503 | United States | 2021-Apr | OUTPAT | Plasma based therapy, SOC | 200 |
| NCT04311177 | United States | 2021-Apr | OUTPAT | ARBs, SOC | 580 |
| NCT04523090 | South Africa | 2021-Apr | OUTPAT | Nitozoxanide | 960 |
| CHICTR2000029589 | China | 2021-Dec | OUTPAT | SOC, Herbal tea | 120 |
| CHICTR2000029539 | China | 2021-Feb | OUTPAT | LPV/r, SOC | 328 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04460690 | United States | 2021-Jul | OUTPAT | Rapid SARS-Cov-2 detection | 5000 |
| NCT04475601 | Sweden | 2021-Jul | OUTPAT | Hormone therapy, SOC | 500 |
| NCT04342689 | United States | 2021-Jun | OUTPAT | Nutrition, SOC | 1500 |
| NCT04418505 | United States | 2021-Mar | OUTPAT | Alternative therapy, SOC | 280 |
| NCT04357990 | Iceland | 2021-Mar | OUTPAT | Alternative therapy, SOC | 128 |
| NCT04400799 | Switzerland | 2021-Mar | OUTPAT | Anticoagulants, SOC | 1000 |
| CHICTR2000030804 | China | 2021-Mar | OUTPAT | SOC, Herbal tea | 128 |
| NCT04353284 | United States | 2021-May | OUTPAT | Camostat, SOC | 114 |
| NCT04331899 | United States | 2021-May | OUTPAT | IFN, SOC | 120 |
| NCT04342169 | United States | 2022-Apr | OUTPAT | HCQ, SOC | 400 |
| NCT04373460 | United States | 2022-Dec | OUTPAT | Plasma based therapy, SOC | 1344 |
| NCT04355767 | United States | 2022-Dec | OUTPAT | Plasma based therapy, SOC | 600 |
| CHICTR2000030084 | China | 2022-Feb | OUTPAT | Psychological therapy, SOC | 180 |
| CTRI/2020/05/025490 | India | NA | OUTPAT | Alternative therapy, SOC | 110 |
| NCT04404218 | Canada | NA | OUTPAT | Acai Berry, SOC | 480 |
| ISRCTN13311119 | India | NA | OUTPAT | Alternative therapy, SOC | 116 |
| JPRN-UMIN000040602 | Brazil | NA | OUTPAT | Alternative therapy, SOC | 100 |
| ISRCTN59048638 | Mexico | NA | OUTPAT | Anticoagulants, SOC | 200 |
| NCT04365582 | France | NA | OUTPAT | AZM, HCQ, LPV/r, SOC | 640 |
| NCT04359329 | United States | NA | OUTPAT | Estrogen steroid hormone, SOC | 110 |
| 2020-002106-68 | United Kingdom | NA | OUTPAT | FPV, LPV/r, LPV/r + FPV, SOC | 240 |
| NCT04346628 | United States | NA | OUTPAT | FPV, SOC | 120 |
| ISRCTN86534580 | United Kingdom | NA | OUTPAT | HCQ, SOC | 3000 |
| 2020-001469-35 | Poland | NA | OUTPAT | HCQ, SOC | 400 |
| NCT04351516 | Germany | NA | OUTPAT | HCQ, SOC | 350 |
| 2020-001558-23 | Italy | NA | OUTPAT | HCQ, SOC | 216 |
| NCT04446429 | Brazil | NA | OUTPAT | Hormone therapy + Ivermectin + AZM, Ivermectin + AZM | 381 |
| NCT04382131 | United Kingdom | NA | OUTPAT | Hygiene, SOC | 405 |
| NCT04412018 | Canada | NA | OUTPAT | Icosapent ethyl, SOC | 100 |
| NCT04445311 | Egypt | NA | OUTPAT | Ivermectin, SOC | 100 |
| NCT04414124 | United States | NA | OUTPAT | KB109 (glycan), SOC | 400 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04405570 | United States | NA | OUTPAT | molnupiravir )N4-hydroxycytidine derivative), SOC | 108 |
| CHICTR2000029387 | China | NA | OUTPAT | Ribavirin+ IFN, Ribavirin + LPV/r + IFN, LPV/r + IFN | 108 |
| CHICTR2000029855 | China | NA | OUTPAT | SOC, Herbal tea | 180 |
| NCT04482673 | United States | NA | OUTPAT | SOC, Vitamin D | 140 |
| CTRI/2020/05/025167 | India | NA | OUTPAT | Thymoquinone, SOC | 100 |
| CHICTR2000030481 | China | 2020-Apr | OUTPAT, HOSP | Corticosteroids, SOC | 200 |
| CHICTR2000030471 | China | 2020-Apr | OUTPAT, HOSP | Nutrition, SOC | 394 |
| CHICTR2000029518 | China | 2020-Apr | OUTPAT, HOSP | SOC, Herbal tea | 140 |
| CHICTR2000029974 | China | 2020-Aug | OUTPAT, HOSP | SOC, Herbal tea | 300 |
| NCT04467918 | Brazil | 2020-Aug | OUTPAT, HOSP | Alternative therapy, SOC | 100 |
| CHICTR2000033318 | China | 2020-Dec | OUTPAT, HOSP | Exercise, SOC | 104 |
| NCT04529499 | Kuwait | 2020-Dec | OUTPAT, HOSP | FPV, SOC | 780 |
| NCT04324463 | Brazil | 2020-Dec | OUTPAT, HOSP | HCQ + AZM, SOC | 4000 |
| NCT04393038 | Belgium | 2020-Dec | OUTPAT, HOSP | Other, SOC | 1034 |
| CHICTR2000029954 | China | 2020-Feb | OUTPAT, HOSP | SOC, Herbal tea | 300 |
| CHICTR2000030102 | China | 2020-May | OUTPAT, HOSP | Non-invasive respiratory support, SOC | 180 |
| NCT04338828 | United States | 2021-Apr | OUTPAT, HOSP | Nitric Oxide, SOC | 260 |
| NCT04390191 | United States | 2021-Apr | OUTPAT, HOSP | Non-invasive respiratory support, SOC | 200 |
| NCT04517396 | United States | 2021-Aug | OUTPAT, HOSP | BIO101 (MAS activator),SOC | 300 |
| IRCT20190810044500N5 | Iran | 2021-Feb | OUTPAT, HOSP | Colchicine, HCQ + Colchicine | 200 |

| | | | | | |
|---|---|---|---|---|---|
| CHICTR2000029867 | China | 2021-Feb | OUTPAT, HOSP | Carrimycin, LPV/r | 520 |
| NCT04394117 | Australia | 2021-Jan | OUTPAT, HOSP | ARBs, SOC | 605 |
| NCT04419025 | United States | 2021-Jan | OUTPAT, HOSP | N-acetyl ccysteine | 200 |
| NCT04500418 | Germany | 2021-Sep | OUTPAT, HOSP | cenicriviroc (CCR2 and CCR5 receptor blocker), SOC | 183 |
| CTRI/2020/06/025763 | India | NA | OUTPAT, HOSP | Alternative therapy | 150 |
| ISRCTN14212905 | United Kingdom | NA | OUTPAT, HOSP | Anticoagulants, Other, SOC | 100 |
| 2020-001498-63 | Belgium | NA | OUTPAT, HOSP | BIO101 (MAS activator) | 465 |
| CHICTR2000029573 | China | NA | OUTPAT, HOSP | cytokine derived gene protein,SOC | 480 |
| NCT04445467 | Australia | NA | OUTPAT, HOSP | FPV, SOC | 190 |
| NCT04336332 | United States | NA | OUTPAT, HOSP | HCQ, HCQ + AZM, SOC | 160 |
| NCT04385095 | United Kingdom | NA | OUTPAT, HOSP | IFN, SOC | 820 |
| ISRCTN14241621 | United Kingdom | NA | OUTPAT, HOSP | IFN, SOC | 220 |
| NCT04354259 | Canada | NA | OUTPAT, HOSP | IFN, SOC | 140 |
| 2020-001860-27 | United Kingdom | NA | OUTPAT, HOSP | multiple drugs, SOC | 250 |
| NCT04377308 | United States | NA | OUTPAT, HOSP | SOC, SSRIs | 2000 |
| 2020-001501-24 | Italy | NA | PREV | HCQ, SOC | 2300 |
| NCT04374942 | Canada | 2020-Aug | PREV | HCQ, SOC | 988 |
| NCT04359537 | Pakistan | 2020-Aug | PREV | HCQ, SOC | 200 |
| CHICTR2000029602 | China | 2020-Aug | PREV | Education + Monitoring + Herbal tea, Psychological therapy | 600 |
| NCT04380701 | Germany | 2020-Aug | PREV | BNT162 RNA Vaccine | 200 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04334928 | Spain | 2020-Dec | PREV | HCQ, HCQ + NRTIs, NRTIs, SOC | 4000 |
| NCT04318015 | Mexico | 2020-Dec | PREV | HCQ, SOC | 400 |
| NCT04348435 | United States | 2020-Dec | PREV | SOC, Stem cells | 100 |
| CHICTR2000031944 | China | 2020-Dec | PREV | SOC, Herbal Tea | 2000 |
| NCT04530357 | Kazakhstan | 2020-Dec | PREV | QAZ-Covid Inactivated Vaccine, SOC | 244 |
| NCT04344379 | France | 2020-Jul | PREV | AZM, HCQ, SOC | 900 |
| NCT04349228 | Tunisia | 2020-Jul | PREV | HCQ, SOC | 530 |
| NCT04366180 | Spain | 2020-Jun | PREV | Nutrition, SOC | 314 |
| NCT04320238 | China | 2020-May | PREV | IFN, IFN + Other | 2944 |
| NCT04421391 | United States | 2020-Nov | PREV | Nutrition | 500 |
| NCT04466280 | Iran | 2020-Nov | PREV | HCQ + mucodentol, mucodentol | 180 |
| NCT04352933 | United Kingdom | 2020-Oct | PREV | HCQ, SOC | 1000 |
| NCT04521322 | Argentina | 2020-Oct | PREV | Iota-Carageenan | 400 |
| NCT04353128 | Spain | 2020-Oct | PREV | Melatonin, SOC | 450 |
| NCT04313023 | United States | 2020-Oct | PREV | PUL-042 (toll-like receptor agonists, SOC | 200 |
| IRCT20200401046909N2 | Iran | 2020-Oct | PREV | SOC, Vitamin D3 | 540 |
| NCT04405908 | Australia | 2020-Oct | PREV | SCB019 (Clover), SOC | 150 |
| NCT04495933 | Australia | 2020-Oct | PREV | SOC, M59 sclamp Vaccine | 216 |
| NCT04384458 | Brazil | 2020-Sep | PREV | HCQ, SOC | 400 |
| NCT04409327 | United States | 2020-Sep | PREV | Other, SOC | 550 |
| NCT04303507 | Thailand | 2021-Apr | PREV | HCQ, SOC | 40000 |
| NCT04349371 | United States | 2021-Apr | PREV | HCQ, SOC | 350 |
| NCT04312243 | United States | 2021-Apr | PREV | Non-invasive respiratory support, SOC | 470 |
| NCT04353037 | United States | 2021-Apr | PREV | HCQ, SOC | 850 |
| NCT04435808 | United States | 2021-Apr | PREV | HCQ, SOC | 350 |
| NCT04321928 | Hungary | 2021-Apr | PREV | Education, Psychological therapy | 7576 |
| NCT04368728 | United States | 2021-Apr | PREV | SOC, Vaccine Pfizer Biontech mRNA Vaccine | 29481 |
| NCT04333732 | United States | 2021-Aug | PREV | HCQ, SOC | 30000 |
| NCT04449276 | Belgium | 2021-Aug | PREV | SOC, CVnCov Vaccine | 168 |
| NCT04461379 | Mexico | 2021-Jan | PREV | SOC, Vaccine | 908 |
| CHICTR2000034780 | China | 2021-Jul | PREV | SOC, Vaccine | 15000 |

| | | | | | |
|---|---|---|---|---|---|
| IRCT20200411047019N1 | Iran | 2021-Jun | PREV | SOC, BCG | 500 |
| NCT04327206 | Australia | 2021-Jun | PREV | Vaccine | 10078 |
| NCT04471519 | India | 2021-Jun | PREV | SOC, Vaccine | 1125 |
| NCT04363450 | United States | 2021-Mar | PREV | HCQ, SOC | 1700 |
| NCT04448119 | Canada | 2021-Mar | PREV | FPV, SOC | 760 |
| NCT04364022 | Switzerland | 2021-Mar | PREV | HCQ, LPV/r | 300 |
| NCT04318444 | United States | 2021-Mar | PREV | HCQ, SOC | 1600 |
| NCT04321174 | Canada | 2021-Mar | PREV | LPV/r, SOC | 1220 |
| NCT04348370 | United States | 2021-May | PREV | SOC, Vaccine | 1800 |
| NCT04364802 | United States | 2021-May | PREV | Hygiene, SOC | 250 |
| NCT04414267 | Greece | 2021-May | PREV | SOC, Vaccine | 900 |
| NCT04530396 | Russia | 2021-May | PREV | SOC, Vaccine Russian Gamelaya Vaccine | 40000 |
| NCT04519437 | United States | 2021-Oct | PREV | mAb, SOC | 940 |
| NCT04456595 | Brazil | 2021-Sep | PREV | SOC, Vaccine | 8870 |
| NCT04536051 | Brazil | 2021-Sep | PREV | Vaccine | 5000 |
| NCT04537949 | Germany | 2021-Sep | PREV | BNT162 RNA Vaccine | 120 |
| NCT04466085 | China | 2021-Sep | PREV | SOC, Vaccine | 900 |
| NCT04372017 | United States | 2022-Apr | PREV | HCQ, Vitamins | 1739 |
| NCT04323800 | United States | 2022-Dec | PREV | Plasma based therapy, SOC | 500 |
| NCT04447781 | South Korea | 2022-Feb | PREV | Device, INO4800 + Device | 160 |
| NCT04299724 | China | 2023-Jul | PREV | aAPC Vaccine | 100 |
| CTRI/2020/05/025275 | India | NA | PREV | Alternative therapy, SOC | 200 |
| NCT04359680 | United States | NA | PREV | Antivirals, SOC | 800 |
| ACTRN12620000417987 | Australia | NA | PREV | HCQ | 680 |
| NCT04340349 | Mexico | NA | PREV | HCQ, bromhexine, SOC | 140 |
| CTRI/2020/05/025067 | India | NA | PREV | HCQ, SOC | 6950 |
| NCT04341441 | United States | NA | PREV | HCQ, SOC | 3000 |
| ACTRN12620000501943 | Australia | NA | PREV | HCQ, SOC | 2250 |
| NCT04334148 | United States | NA | PREV | HCQ, SOC | 2000 |
| 2020-001987-28 | Italy | NA | PREV | HCQ, SOC | 1000 |
| NCT04349228 | Tunisia | NA | PREV | HCQ, SOC | 530 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04496245 | Australia | NA | PREV | Immunomodulators, SOC | 1000 |
| NCT04452773 | Spain | NA | PREV | Manremyc food supplement | 315 |
| NCT04408183 | United States | NA | PREV | quinine topical nasal spary | 225 |
| NCT04379336 | South Africa | NA | PREV | SOC, BCG | 500 |
| ISRCTN50212645 | United Kingdom | NA | PREV | Other | 2000 |
| CTRI/2020/05/025429 | India | NA | PREV | Alternative therapy, SOC | 5000 |
| NCT04343248 | United States | NA | PREV | Antivirals, SOC | 800 |
| SLCTR/2020/011 | Sri Lanka | NA | PREV | HCQ, SOC | 400 |
| CTRI/2020/06/025928 | India | NA | PREV | Hygiene | 204 |
| NCT04344600 | United States | NA | PREV | IFN, SOC | 164 |
| NCT04399252 | United States | NA | PREV | Nutrition, SOC | 1000 |
| CTRI/2020/05/025277 | India | NA | PREV | Other, SOC | 4000 |
| CHICTR2000032459 | China | NA | PREV | SOC, Inactivated SARS-Cov-2 (Vero cell) Vaccine | 288 |
| NCT04475302 | India | NA | PREV | SOC, Vaccine | 2175 |
| NCT04368988 | United States | NA | PREV | SOC, Vaccine | 1631 |
| NCT04369794 | Brazil | NA | PREV | SOC, Vaccine | 1000 |
| NCT04470427 | United States | NA | PREV | SOC, Vaccine mRNA1273 | 30000 |
| CTRI/2020/06/025769 | India | NA | PREV | Alternative therapy, SOC | 40000 |
| CTRI/2020/05/025484 | India | NA | PREV | Alternative therapy, SOC | 5000 |
| CTRI/2020/05/025491 | India | NA | PREV | Alternative therapy, SOC | 1000 |
| CTRI/2020/07/026560 | India | NA | PREV | Alternative therapy, SOC | 200 |
| IRCT20130306012728N8 | Iran | NA | PREV | HCQ, SOC | 500 |
| NCT04387409 | Germany | NA | PREV | SOC, Vaccine | 1200 |
| NCT04384549 | France | NA | PREV | SOC, Vaccine | 1120 |
| NCT04381988 | United States | NA | PREV | HCQ + Radiation therapy, Radiation therapy | 132 |
| 2020-002287-31 | Spain | NA | PREV | HCQ, SOC | 1930 |
| ISRCTN17072692 | United Kingdom | NA | PREV | LNP-nCoVsaRNA Vaccine | 320 |
| NCT04357028 | Egypt | NA | PREV | measles vaccine, SOC | 200 |
| NCT04445389 | South Korea | NA | PREV | SOC, GX-19 DNA Vaccine | 210 |
| NCT04470609 | China | NA | PREV | SOC, SARS-Cov-2 inactivated vaccine | 471 |
| NCT04439045 | Canada | NA | PREV | SOC, Vaccine | 3626 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04445428 | Guinea-Bissau | NA | PREV | SOC, Vaccine | 3400 |
| ISRCTN89951424 | Brazil | NA | PREV | SOC, Vaccine | 2000 |
| NL8547 | Netherlands | NA | PREV | SOC, Vaccine | 1600 |
| NCT04442048 | Canada | NA | PREV | SOC, Vaccine | 1500 |
| ISRCTN15281137 | United Kingdom | NA | PREV | SOC, Vaccine | 1112 |
| CTRI/2020/07/026352 | India | NA | PREV | SOC, Vaccine | 1048 |
| NCT04436276 | United States | NA | PREV | SOC, Vaccine | 1045 |
| NCT04412538 | China | NA | PREV | SOC, Vaccine | 942 |
| RPCEC00000314 | Cuba | NA | PREV | SOC, Vaccine Finlay Vaccine Institute | 115000 |
| ISRCTN90906759 | United Kingdom | NA | PREV | Vaccine | 12330 |
| CTRI/2020/06/025861 | India | NA | PREV | Alternative therapy, SOC | 500 |
| NCT04498442 | United States | NA | PREV | Exercise, Other, Respiratory support | 30000 |
| CHICTR2000030937 | China | 2020-Aug | TAIL | SOC, Herbal tea | 144 |
| CHICTR2000030720 | China | 2020-Aug | TAIL | SOC, Herbal tea | 120 |
| NCT04368845 | Greece | 2020-Jul | TAIL | Non-invasive respiratory support, SOC | 100 |
| CHICTR2000030987 | China | 2020-Jun | TAIL | FPV, FPV + HCQ, SOC | 150 |
| NCT04333589 | China | 2020-Jun | TAIL | FPV, SOC | 210 |
| NCT04394169 | Spain | 2020-Sep | TAIL | Rehabilitation, SOC | 102 |
| CHICTR2000029789 | China | 2021-Jun | TAIL | SOC, Herbal tea | 100 |
| CHICTR2000030920 | China | 2021-May | TAIL | SOC, Herbal tea | 100 |
| NCT04351880 | United States | NA | TAIL | Meal planning | 640 |
| NCT04279197 | China | NA | TAIL | SOC, Herbal tea | 160 |
| CHICTR2000029578 | China | 2020-Apr | UNCLEAR | Alternate therapy | 1000 |
| NCT04365309 | China | 2020-Apr | UNCLEAR | Antihypertensive, SOC | 128 |
| NCT04319900 | China | 2020-Apr | UNCLEAR | FPV, HCQ + FPV, SOC | 150 |
| CHICTR2000031204 | China | 2020-Apr | UNCLEAR | HCQ, SOC | 300 |
| CHICTR2000030923 | China | 2020-Apr | UNCLEAR | SOC, Herbal tea | 400 |
| CHICTR2000029517 | China | 2020-Apr | UNCLEAR | SOC, Herbal tea | 100 |
| NCT04326790 | Gibraltar | 2020-Aug | UNCLEAR | Colchicine, SOC | 180 |
| NCT04527562 | Bangladesh | 2020-Dec | UNCLEAR | Colchicine, SOC | 300 |
| CHICTR2000032915 | China | 2020-Dec | UNCLEAR | HCQ, AZM, SOC | 240 |

| | | | | | |
|---|---|---|---|---|---|
| CHICTR2000030219 | China | 2020-Dec | UNCLEAR | Herbal tea | 120 |
| NCT04447235 | Brazil | 2020-Dec | UNCLEAR | Ivermectin + ARBs, SOC | 176 |
| NCT04323345 | Egypt | 2020-Dec | UNCLEAR | Nutrition, SOC | 1000 |
| CHICTR2000033320 | China | 2020-Dec | UNCLEAR | SOC, Herbal tea | 300 |
| CHICTR2000030288 | China | 2020-Dec | UNCLEAR | SOC,Herbal tea | 204 |
| CHICTR2000032098 | China | 2020-Jul | UNCLEAR | Herbal tea | 300 |
| CHICTR2000030480 | China | 2020-Jul | UNCLEAR | IFN, SOC | 328 |
| NCT04425707 | Egypt | 2020-Jul | UNCLEAR | Ivermectin, SOC | 100 |
| CHICTR2000032399 | China | 2020-Jul | UNCLEAR | SOC, Herbal tea | 200 |
| NCT04334265 | China | 2020-Jun | UNCLEAR | Alternative therapy, SOC | 750 |
| NCT04392141 | Iran | 2020-Jun | UNCLEAR | Colchicine + Alternative therapy, SOC | 200 |
| CHICTR2000032237 | China | 2020-Jun | UNCLEAR | SOC, Herbal tea | 200 |
| CHICTR2000030034 | China | 2020-Jun | UNCLEAR | SOC, Herbal tea | 132 |
| CHICTR2000032400 | China | 2020-Jun | UNCLEAR | SOC, Herbal tea | 120 |
| CHICTR2000030490 | China | 2020-Mar | UNCLEAR | Herbal tea | 100 |
| CHICTR2000030535 | China | 2020-Mar | UNCLEAR | LPV/r + IFN, LPV/r + IFN + Other | 100 |
| CHICTR2000030188 | China | 2020-Mar | UNCLEAR | SOC, Herbal tea | 120 |
| CHICTR2000030810 | China | 2020-Mar | UNCLEAR | SOC, Herbal tea | 100 |
| CHICTR2000029550 | China | 2020-May | UNCLEAR | Herbal tea | 300 |
| CHICTR2000029558 | China | 2020-May | UNCLEAR | Herbal tea | 200 |
| CHICTR2000029549 | China | 2020-May | UNCLEAR | SOC, Herbal tea | 400 |
| CHICTR2000029778 | China | 2020-May | UNCLEAR | SOC, Herbal tea | 600 |
| NCT04405843 | Colombia | 2020-Nov | UNCLEAR | Ivermectin, SOC | 400 |
| NCT04355936 | Argentina | 2020-Oct | UNCLEAR | Antihypertensive, SOC | 400 |
| NCT04312997 | United States | 2020-Oct | UNCLEAR | PUL-042 (toll-like receptor agonists, SOC | 100 |
| CHICTR2000029790 | China | 2020-Oct | UNCLEAR | SOC, Herbal tea | 120 |
| NCT04353336 | Egypt | 2020-Sep | UNCLEAR | HCQ | 200 |
| NCT04325893 | France | 2020-Sep | UNCLEAR | HCQ, SOC | 1300 |
| NCT04429711 | Israel | 2020-Sep | UNCLEAR | Ivermectin, SOC | 100 |
| NCT04463264 | Argentina | 2020-Sep | UNCLEAR | Nitazoxanide, SOC | 135 |
| NCT04338698 | Pakistan | 2020-Sep | UNCLEAR | Oseltamavir vs Azithromycin vs HCQ | 500 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04449588 | China | 2021-Aug | UNCLEAR | BDB001 (toll like receptor agonist), SOC | 368 |
| CHICTR2000030117 | China | 2021-Dec | UNCLEAR | LPV/r + IFN, Herbal tea | 348 |
| CHICTR2000029935 | China | 2021-Feb | UNCLEAR | HCQ | 100 |
| CHICTR2000029939 | China | 2021-Feb | UNCLEAR | HCQ, SOC | 100 |
| NCT04421508 | United States | 2021-Feb | UNCLEAR | Non-invasive respiratory support, SOC | 500 |
| CHICTR2000029605 | China | 2021-Feb | UNCLEAR | SOC, Herbal tea | 400 |
| CHICTR2000029747 | China | 2021-Feb | UNCLEAR | SOC, Herbal tea | 200 |
| IRCT20110726007117N11 | Iran | 2021-Jan | UNCLEAR | SOC, Vitamin D | 210 |
| NCT04334512 | United States | 2021-Jun | UNCLEAR | HCQ,AZM, Vitamins, Zinc | 600 |
| NCT04344041 | France | 2021-May | UNCLEAR | ,Vitamin D, SOC | 260 |
| CHICTR2000032919 | China | 2021-May | UNCLEAR | SOC, Herbal tea | 200 |
| NCT04395768 | Australia | 2021-Sep | UNCLEAR | HCQ + AZM + Zinc + Vitamins | 200 |
| CHICTR2000029756 | China | 2022-Feb | UNCLEAR | IFN, Herbal tea | 238 |
| CHICTR2000029976 | China | 2022-Feb | UNCLEAR | Psychological therapy, SOC | 160 |
| CTRI/2020/06/026221 | India | NA | UNCLEAR | Alternative therapy, HCQ | 100 |
| CTRI/2020/06/025557 | India | NA | UNCLEAR | Alternative therapy, SOC | 420 |
| CTRI/2020/07/026468 | India | NA | UNCLEAR | Alternative therapy, SOC | 140 |
| NCT04351347 | Egypt | NA | UNCLEAR | Antivirals, HCQ, Ivermectin | 300 |
| CHICTR2000032769 | China | NA | UNCLEAR | Azuvidine, SOC | 342 |
| NCT04471766 | Guinea-Bissau | NA | UNCLEAR | Cloth face mask, SOC | 66000 |
| CTRI/2020/05/025320 | India | NA | UNCLEAR | Exercise + Nutrition + Hygiene + Alternative therapy + Other, SOC | 658 |
| CTRI/2020/06/025575 | India | NA | UNCLEAR | HCQ + ribavirin, LPV/r + ribavirin | 175 |
| NCT04374019 | United States | NA | UNCLEAR | HCQ, HCQ + AZM, HCQ + Ivermectin, Other | 240 |
| NCT04447534 | Egypt | NA | UNCLEAR | HCQ, HCQ + Zinc | 200 |
| NCT04403555 | Egypt | NA | UNCLEAR | HCQ, Ivermectin + Docycline | 200 |
| NCT04410562 | Spain | NA | UNCLEAR | HCQ, SOC | 714 |
| NCT04352959 | France | NA | UNCLEAR | Hygiene, SOC | 178 |
| RPCEC00000307 | Cuba | NA | UNCLEAR | IFN | 120 |
| CHICTR2000029638 | China | NA | UNCLEAR | IFN | 100 |
| CHICTR2000030262 | China | NA | UNCLEAR | IFN, SOC | 140 |
| NCT04255017 | China | NA | UNCLEAR | LPV/r, Oseltamivir, SOC, Umifenovir | 400 |

| REGISTRATION ID | Country | EXPECTED COMPLETION | SUBJECTS | AGENTS STUDIED | NO OF SUBJECTS |
|---|---|---|---|---|---|
| IRCT20200506047319N1 | Iran | 2020-Jul | HOSP | Alternative therapy, SOC | 100 |
| IRCT20200607047675N1 | Iran | 2020-Sep | HOSP | Alternative therapy, SOC | 100 |
| IRCT20200610047722N1 | Iran | 2020-Jul | HOSP | Alternative therapy, SOC | 100 |
| IRCT20080901001165N48 | Iran | 2020-Jul | HOSP | Alternative therapy, SOC | 100 |
| IRCT20200504047298N1 | Iran | 2020-Jun | HOSP | Antiretrovirals, LPV/r | 100 |
| CHICTR2000032456 | China | 2020-May | HOSP | Education + Non-invasive respiratory support, SOC | 100 |
| IRCT20150808023559N20 | Iran | 2020-Jul | HOSP | FPV + HCQ, HCQ + LPV/r | 100 |
| IRCT20200322046833N1 | Iran | 2020-Apr | HOSP | HCQ + Antiretrovirals, HCQ + Antiretrovirals + Umifenovir | 100 |
| NCT04343092 | Iraq | 2020-May | HOSP | HCQ + AZT, HCQ + AZT + Other | 100 |
| IRCT20200317046797N3 | Iran | 2020-Jul | HOSP | HCQ + LPV/r + Antivirals, Igs + HCQ + LPV/r + Antivirals | 100 |
| IRCT20180725040596N2 | Iran | 2020-Sep | HOSP | HCQ + LPV/r, HCQ + Umifenovir | 100 |
| IRCT20200418047126N1 | Iran | 2020-Jun | HOSP | HCQ, HCQ + Colchicine | 100 |
| IRCT20190418043307N1 | Iran | 2020-Jun | HOSP | HCQ, HCQ + Ivermectin | 100 |
| IRCT20200325046859N2 | Iran | 2020-Jun | HOSP | HCQ, HCQ + Umifenovir | 100 |
| IRCT20080901001165N53 | Iran | 2020-Aug | HOSP | IFN, SOC | 100 |
| IRCT20151227025726N15 | Iran | 2020-Jul | HOSP | LPV/r, Umifenovir | 100 |
| IRCT20200324046850N1 | Iran | 2020-Jul | HOSP | N-Acetyl-cysteine, SOC Vitamin D3, Vitamin D3 + N-Acetyl-cysteine | 100 |

| | | | | | |
|---|---|---|---|---|---|
| IRCT20200525047562N1 | Iran | 2020-Jul | HOSP | Plasma based therapy, SOC | 100 |
| IRCT20080901001165N58 | Iran | 2020-Jun | HOSP | Plasma based therapy, SOC | 100 |
| IRCT20190727044343N2 | Iran | 2020-Apr | HOSP | SOC, Statins | 100 |
| NCT04288102 | China | 2020-May | HOSP | SOC, Stem cells | 100 |
| NCT04363736 | United States | 2020-Aug | HOSP | TCZ | 100 |
| IRCT20120225009124N4 | Iran | 2020-Jun | HOSP | Corticosteroids + Igs + IFN, HCQ + Antivirals | 105 |
| IRCT20200402046923N1 | Iran | 2020-May | HOSP | Alternative therapy, SOC | 110 |
| IRCT20200415047092N1 | Iran | 2020-May | HOSP | AZT + Oseltamivir + LPV/r + Antiretroviral + HCQ, Oseltamivir + LPV/r + Antiretroviral + HCQ | 110 |
| IRCT20200411047025N1 | Iran | 2020-May | HOSP | HCQ + Antiretroviral, HCQ + Antiretroviral + Vitamins | 110 |
| IRCT20171122037571N2 | Iran | 2020-May | HOSP | Remdesivir + Chloroqines + LPV/r or Atazanavir | 120 |
| IRCT20200405046951N1 | Iran | 2020-Aug | HOSP | SOC, Vitamin A | 120 |
| NCT04276688 | China | 2020-Mar | HOSP | LPV/r, LPV/r + IFN | 127 |
| NCT04473170 | United Arab Emirates | 2020-May | HOSP | SOC, Stem cells | 146 |
| IRCT20200316046792N1 | Iran | 2020-May | HOSP | Alternative therapy, SOC | 150 |
| IRCT20200411047016N1 | Iran | 2020-Jun | HOSP | Alternative therapy, SOC | 150 |
| IRCT20200705048013N1 | Iran | 2020-Jul | HOSP | HCQ + Vitamins + Non- | 150 |

| | | | | | |
|---|---|---|---|---|---|
| | | | | invasive respiratory support + Plasma based therapy, Other | |
| CHICTR2000029308 | China | 2021-Jan | HOSP | LPV/r, SOC | 160 |
| IRCT20200325046860N1 | Iran | 2020-Aug | HOSP | Conv plasma, SOC | 200 |
| IRCT20160310026998N11 | Iran | 2020-Apr | HOSP | metformin, SOC | 200 |
| IRCT20080901001165N46 | Iran | 2020-Aug | HOSP | SOC, Umifenovir | 200 |
| CHICTR2000030254 | China | NA | HOSP | FPV, Umifenovir | 240 |
| NCT04323527 | Brazil | 2020-May | HOSP | HCQ | 278 |
| IRCT20200318046812N1 | Iran | 2020-Jun | HOSP | HCQ + FPV, HCQ + LPV/r | 324 |
| IRCT20160316027081N1 | Iran | 2020-Apr | HOSP | licorice, SOC | 374 |
| NCT04327388 | Argentina | 2020-Jul | HOSP | Sarilumab, SOC | 421 |
| NCT04321278 | Brazil | 2020-Jun | HOSP | HCQ, HCQ + AZT | 440 |
| NCT04320615 | United States | 2020-Jun | HOSP | SOC, TCZ | 450 |
| NCT04332991 | United States | 2020-Jun | HOSP | HCQ, SOC | 479 |
| IRCT20200624047908N1 | Iran | 2020-Sep | HOSP | DAA, SOC | 1000 |
| NCT04280705 | United States | 2020-May | HOSP | Remdesivir, SOC | 1062 |
| NCT04292899 | United States | 2020-Apr | HOSP | Remdesivir | 4891 |
| IRCT20200510047383N1 | Iran | 2020-Aug | HOSP | SOC, TCZ | 100 |
| IRCT20200508047345N1 | Iran | 2020-Jun | OUTPAT | Alternative therapy | 100 |
| IRCT20200415047089N1 | Iran | 2020-May | OUTPAT | Alternative therapy, SOC | 100 |
| NCT04349241 | Egypt | 2020-Jun | OUTPAT | FPV, SOC | 100 |
| IRCT20160313027033N2 | Iran | 2020-May | OUTPAT | Nutrition, SOC | 120 |
| NCT04483830 | Mexico | 2020-Aug | OUTPAT | Anticoagulants, SOC | 243 |
| NCT04365738 | Turkey | 2020-Apr | OUTPAT | Education, Non-invasive respiratory support | 270 |
| NCT04304053 | Spain | 2020-Jun | OUTPAT | HCQ + Antivirals, SOC | 2300 |
| IRCT20160625028622N1 | Iran | 2020-Apr | OUTPAT | Noscapine, SOC | 125 |
| NCT04337541 | Denmark | 2020-Jun | PREV | Surgical Face mask, SOC | 6000 |

| | | | | | |
|---|---|---|---|---|---|
| IRCT20200503047280N1 | Iran | 2020-Jul | PREV | Alternative therapy, SOC | 300 |
| IRCT20190122042450N4 | Iran | 2020-Jun | PREV | HCQ, SOC | 1000 |
| IRCT20140428017469N1 | Iran | 2020-Jul | PREV | oral polio vaccine | 130000 |
| NCT04308668 | United States | 2020-May | PREV | HCQ, SOC | 1309 |
| NCT04392219 | United Kingdom | 2020-Aug | PREV | EIDD-2801, SOC | 130 |
| CHICTR2000034825 | China | 2020-Dec | PREV | SOC,Inovio DNA plasmid vaccine | 144 |
| NCT04408456 | India | 2020-Jul | PREV | HCQ, SOC | 325 |
| CHICTR2000029479 | China | 2020-May | PREV | SOC, TCM | 20000 |
| NCT04342650 | Brazil | 2020-May | PREV | Chloroquine diphosphate, SOC | 152 |
| IRCT20171105037262N4 | Iran | 2020-Jul | UNCLEAR | HCQ, HCQ + adalimumab | 100 |
| IRCT20200410047009N1 | Iran | 2020-Jul | UNCLEAR | NSAIDs, SOC | 101 |
| IRCT20200408046987N1 | Iran | 2020-Jun | UNCLEAR | Ivermectin, SOC | 125 |
| IRCT20200404046934N1 | Iran | 2020-Apr | UNCLEAR | Alternative therapy, SOC | 130 |
| IRCT20180520039738N2 | Iran | 2020-Apr | UNCLEAR | SOC, Vitamin A | 140 |
| IRCT20131129015584N2 | Iran | 2020-Jun | UNCLEAR | LPV/r + AZM, LPV/r + AZM + Alternative therapy | 152 |
| CHICTR2000032165 | China | 2021-Mar | UNCLEAR | Education, TCM + Education | 160 |
| CHICTR2000029434 | China | 2020-Dec | UNCLEAR | SOC, TCM | 240 |
| CHICTR2000029433 | China | 2020-Dec | UNCLEAR | SOC, TCM | 240 |
| NCT04530422 | Egypt | 2020-Jul | UNCLEAR | DAA, Oseltamivir + HCQ + AZM | 250 |
| CHICTR2000029559 | China | 2020-Feb | UNCLEAR | HCQ, SOC | 300 |
| CHICTR2000029868 | China | 2020-Jun | UNCLEAR | HCQ, SOC | 360 |

| | | | | | |
|---|---|---|---|---|---|
| NCT04523831 | Bangladesh | 2020-Aug | UNCLEAR | Ivermectin + Antibiotics, SOC | 400 |
| NCT04446104 | Singapore | 2020-Aug | UNCLEAR | HCQ, Hygiene, Ivermectin, Vitamins, Vitamins + Zinc | 4257 |

SUPPLEMENTARY TABLE 2: TRIALS COMPLETED AS OF NOVEMBER 1, 2020. The registration ID for the respective regulatory body is given along with the country of registration and the date of completed enrolment. The setting for subjects in each trial: HOSP: Hospitalized; PREV: Healthy or exposed volunteers; OUTPAT: Infected patients, not hospitalized; UNCLEAR: Including multiple categories. SOC: Standard of Care.; FPV: Favipiravir; LPV/R: lopanovir/ritonavir; HCQ: hydroxychloroquine; AZM: azithromycin; TCM: A Chinese herbal tea; NSAID: Non-steroidal anti-inflammatory drug; Conv Plasma: Convalescent plasma